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ABSTRACT 
 
Improving the Anti-HIV Potency of Different Compounds through Synergy and Covalent 
Linkage:  Dimerization Studies of CXCL8. 
(August 2010) 
Ioannis Kagiampakis, B.S.; M.S., University of Crete, Greece 
Co-Chairs of Advisory Committee: Dr. Patricia LiWang 
 Dr. Martin J. Scholtz 
 
 
In the first part of my dissertation we focused on the development of covalently 
linking compounds that bind gp120 with those that bind gp41 in order to block HIV 
fusion.  We used griffithsin or CD4M33, that both bind to gp120, covalently linked with 
C-peptide C37 of gp41.  The results show the linked compound Griff37 is several-fold 
more potent than griffithsin alone in both fusion and viral assay, making Griff37 an 
attractive candidate for further development as a microbicide against HIV. 
In the second part of my dissertation we investigate the effect of combining HIV 
fusion inhibitors having differing mechanisms of action. We used P2-RANTES and 
RANTES that both bind to the chemokine receptor CCR5 on the surface of the human 
cells along with C-peptides C37 and C34 that bind the viral envelop glycoprotein gp41.  
We found that the combination of RANTES with C37/C34 has an additive effect on 
fusion assay.  In contrast P2-RANTES and C37/C34 shows synergy in inhibition of cell 
fusion.  In viral assays using MAGI cells the synergy between P2-RANTES and C37/C34 
is minimal.  
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In the third part of my dissertation we focused on characterization of two 
examples of evolutionarily conserved unfavorable sequence motifs that affect quaternary 
structure.  In contrast to the straightforward action of favorable sequences, these 
unfavorable motifs produce interactions disfavoring one outcome to indirectly promote 
another one.  To identify such motifs, we propose and developed a statistically validated 
computational method combining structure and phylogeny.  This approach was applied in 
an analysis of the alternate forms of homodimerization exhibited in the chemokine 
family.  We identified two evolutionarily conserved sequence motifs in the CC 
subfamilies: a drastic two-residue deletion (∆RV) and a simple point mutation (V27R). 
Cloned into the CXCL8 background, these two motifs were experimentally proven to 
confer a monomeric state.  NMR analyses indicate that these variants are structured in 
solution and retain the chemokine fold.  Structurally, the motifs retain a chemokine 
tertiary fold while introducing unfavorable quaternary interactions that inhibit CXCL8 
dimerization.   
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CHAPTER I  
INTRODUCTION AND BACKGROUND  
AIDS Epidemics 
 
According to the World Health organization (WHO) 
(http://www.who.int/hiv/pub/epidemiology/epidemic/en/index.html), in 2008 an 
estimated 33.4 million people worldwide were living with HIV.  Of that number, 31.3 
million were adults and 15.7 million were women.  In that same year, 2.7 million were 
infected with HIV, the majority of them (2.3 million) adults.  There were 2 million AIDS 
related deaths in 2008.   
 AIDS is a global epidemic concentrated in Sub-Saharan Africa. An estimated 22.4 
million adults live with HIV in that area, and this represents 5.2% of the total population.  
The following list adopted by WHO gives details on current epidemiological statistics on 
HIV/AIDS (Figure I-1). 
Although new incidences of HIV are on the decline and there are indications of 
success in HIV prevention, the battle against HIV is far from concluded.  Currently there 
is no cure against HIV, with a single possible exception: there is one case where the 
transplantation of CCR5 ∆32/∆32 stem cells into a patient with acute myeloid leukemia 
and an HIV-1 infection showed no detectable virus for more than 1.5 years post-
transplantation (67).  
_______________ 
This dissertation follows the style of Journal of Virology. 
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Figure I-1:  Regional HIV and AIDS statistics, 2008.  
Adopted by WHO 
(http://www.who.int/hiv/pub/epidemiology/epidemic/en/index.html) 
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People who naturally have the CCR5 ∆32/∆32 mutation do not express CCR5 on 
their cell surface and show resistance to HIV-1 infection since CCR5 plays a key role in 
the infection process, as I will describe later in this chapter.  There are also no vaccines 
against HIV.  Recently in Thailand, a clinical trial of the combination of two vaccines 
(RV144 trial), one of them immunizing against the viral envelope glycoprotein gp120, 
and the other against HIV replication, failed to give solid conclusions about the 
usefulness of this combination (94). 
In clinical use today are antiretroviral drugs that can be categorized into the 
following four groups:  
1) Reverse transcriptase inhibitors (RTIs) (This group is further divided into three 
subcategories: a) nucleoside inhibitors, b) nucleotide analogues inhibitors (NRTIs), c) 
nonnucleoside inhibitors (NNRTIs)).  Their role is to inhibit the reverse transcription of 
the viral genome.   
2) Protease inhibitors (PI) that block the maturation of viral proteins,  
3) Integrase inhibitors that inhibit the integration of the viral genome into the host 
chromosome and  
4) Fusion inhibitors that block the fusion of the virion to the target cell (9).   
Combination treatment of HIV patients with antiretroviral drugs (usually a triple 
combination of two NRTIs together with one PI or one NNRTI) succeeds in most cases 
to drop the viral load to undetectable levels.  In ~5% of cases, therapy fails and the virus 
rebounds.  It is obvious that until the development of a successful vaccine emerges, a race 
between virus adaptation and new anti-HIV drug development will take place.  Most of 
my dissertation is focusing on the development of new anti-HIV fusion inhibitors that can 
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be used as a vaginal microbicide.  The importance of microbicide development can be 
appreciated by the results of epidemiological studies from WHO that recognize that 
heterosexual intercourse is the leading cause of virus spread.  Transition probability per 
exposure event is 1 in 200 to 1 in 2000 for the female genital tract and 1 in 700 to 1 in 
3000 for the male genital tract (65, 66). An effective HIV microbicide for the female 
genital tract will provide an extra “weapon” in HIV prevention, especially in third world 
countries where the use of condoms may not be a woman’s choice.  
HIV host invasion 
One of the biggest challenges in developing an HIV microbicide is finding a 
compound that will inhibit the multiple ways the virus has adapted to penetrate the 
human epithelium and infected different target cells without the compound causing 
inflammation at the area of application.  In other words, the microbicide needs to be at 
the proper “place” at the proper time in order to be effective and to not recruit 
inflammatory cells that are the targets of HIV.  In the following paragraph I will describe 
current knowledge on virus invasion, focusing on the vaginal epithelium.  
 It has been shown that during heterosexual intercourse, women can acquire HIV 
through the non-keratinized squamous epithelium of the vagina and endocervix and the 
single-layer columnar epithelium of the endocervix. Men can be infected through the 
inner foreskin of the penis and the penile urethra (65, 66). 
 But how does HIV actually penetrate the mucosa during heterosexual intercourse 
in women?  Five cells types (Epithelial cells, Langerhans cells, Dendritic cells, T-cells 
and Macrophages) that exist in the epithelium and stroma of the vagina and uterine 
ectocervix play key roles in HIV invasion (Figure I-2). 
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Figure I-2:  Cells that exist in vaginal epithelium and stroma. 
These cells play key roles in HIV host invasion through heterosexual intercourse. 
Figure adopted by (66). 
 
 
There are many models that describe how HIV infects the genital mucosa in 
women.  The most recent ones are: 
1) Macro – abrasion of the epithelium allows free virus or infected donor cells to 
invade deep into the epithelium (stroma) where DCs, T-cells and macrophages 
are abundant.  These 3 cells types can cause productive HIV infection and 
transfer the virion to the lymph nodes (65, 66). 
2)  Free HIV virions can be trapped in mucus and move inside the epithelium 
through gaps between epithelial cells.  Langerhans cells are inside the 
epithelium and are the first cells the virion encounters.  Inside these cells, the 
virion can be degraded in Birbeck granules or cause a productive infection.  
Infected Langerhans cells can migrate into the submucosa and through venous 
microvessels to lymph nodes.  Inside the epithelial layer but deeper than 
Langerhans cells, can also be found resting memory T cells and dendritic 
cells.  Virions can productively infect both these types of cells and migrate to 
lymph nodes (65, 66). 
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3) Free virions can move deeper into the epithelial layer via transcytosis through 
epithelial cells, especially near the basal level of the squamous epithelium (65, 
66).  
Infection of T-cells by the HIV-1 free virion 
 T-cells may not be the first cells that the virus encounters and can infect 
productively as it gets deeper in the vagina epithelium, but these are the cells that have 
been studied the most on a molecular basis and that I have used as a model system to test 
the new drug design.  A detailed description of the HIV fusion process on a molecular 
level will follow.  
 The viral spike consists of two heavily glycosylated proteins named gp120 and 
gp41.  Both of these proteins form trimers (Figure I-3) (154).  Before human-virus 
interaction, gp120 structurally covers gp41 and gp41 has a transmembrane domain that 
anchors the spike on the viral membrane.  The HIV-1 virion has, on average, 14 ± 7 
spikes on its surface (197).   
 
 
Figure I-3:  HIV-1 spike consists of glycoproteins gp120 and gp41. 
T-cell has CD4 (receptor) and CCR5 or CXCR4 (coreceptors) on its surface. 
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The first step of the fusion process is the interaction of viral glycoprotein gp120 
with the T-cell surface receptor CD4 (Figure I-3).  Gp120–CD4 interaction causes 
conformational changes to gp120, revealing cryptic epitopes that are located in the V3 
domain and the bridging sheet of gp120 (27).  These epitopes allow interaction between 
gp120 and the chemokine receptor CXCR4 or CCR5 (coreceptors).  In this state, the viral 
spike is considered in the “open” form.  After this initial interaction the number of HIV-1 
receptors and coreceptors is increased in the vicinity (193) (Figure I-4). 
 
 
 
 
Figure I-4:  HIV spike.   
A) “Closed” form of the HIV-1 spike.  Gp120 covers almost all of gp41.  The initial 
interaction of gp120-CD4 results in the accumulation of receptors and coreceptors 
in the vicinity of the initial interaction.  B) “Open” form of the viral spike.  Gp41 is 
extended and accessible.  Conformational changes in gp120 allow cryptic epitopes to 
be exposed.  These epitopes will facilitate the interaction of gp120 with coreceptors 
(CCR5 or CXCR4). 
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Gp120–CD4 interaction does not only induce conformational changes to gp120 
but also to gp41, allowing it to be in a more extended form.  Gp41 consists of a 
cytoplasmic domain (CD), a transmembrane domain (TM), a C-terminal heptad repeat 
(CHR), an N-terminal heptad repeat (NHR) and a fusion peptide that is located on the N-
terminal tip of the protein (Figure I-5).  When the spike is in the “open” form, the NHR 
of gp41 is accessible for C-peptide fusion inhibitors (C-peptide fusion inhibitors bind to 
the NHR area of gp41) (13, 135).  I will talk about them later in detail. 
 
 
 
 
Figure I-5:  gp41 domains 
 
 
 
 The next step in the fusion process is the interaction of gp120 with the coreceptors 
(Figure I-6).  There is a long list of coreceptors that the HIV-1 virus can use to enter the 
cell (195), but the main coreceptors for T-cells are the chemokine receptors CCR5 and 
CXCR4.  Both of them are G-protein coupled receptors.  Which coreceptor a virus uses 
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to enter the cell dictates its tropism: R5-tropic or X4-tropic, respectively.  If the virus 
uses both receptors then it is called R5/X4 tropic (135).   
The gp120–CCR5/CXCR4 interaction results in the activation of the chemokine 
receptor and signaling.  It has been shown that blocking intracellular Ca2+ release with 
protein kinase C inhibitors interferes with virion-targeted cell fusion (55).  There is an 
accumulating body of evidence that viral-induced signaling is important for T-cell 
migration, adhesion and survival (192).  It has also been suggested that this signaling 
affects post-fusion events like viral transcription (39, 97). 
 
 
 
 
Figure I-6:  Interaction of gp120 with the chemokine receptor CCR5 and CXCR4. 
The fusion peptide (FP) of gp41 has inserted into the target cell membrane. 
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 Currently we do not know if all three gp120 subunits of one spike interact with 
three CD4 receptors or if they interact with three coreceptors, but there is evidence that 
more than one spike is needed for pore formation and HIV-1 fusion (164).  The current 
hypothesis is that after gp120-coreceptor interaction, the fusion peptide (FP) of gp41 that 
is hydrophobic is inserted into the membrane of T-cells.  At this point we do not have 
pore formation yet; only lipid mixing of the viral envelope and cell membrane is 
occurring (107) (Figure I-7). 
 
 
 
 
Figure I-7:  Lipid mixing between viral and target cell membrane. 
Red color indicates viral lipids. For simplicity, only gp41 is shown. 
 
 
 
The HIV virion may enter the cell via endocytosis and fuse with endosomes in a 
dynamin-dependent matter.  After the virion is inside the cell we observe pore formation 
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and the release of the capsid into the cell cytoplasm (113).  A significant role in pore 
formation is played by the gp41 protein that forms a six-helix bundle when the C-
terminal heptad repeat (CHR) interacts with the N-terminal heptad repeat (NHR)(114) 
(Figure I-8).  C-peptides C37 and C34, which are considered fusion inhibitors, block the 
formation of this helix bundle.  This formation is believed to stabilize the pore (107).  
The pore needs to be big enough and stable enough for the viral capsid to enter the target 
cell’s cytoplasm. 
 
 
 
 
Figure I-8:  Pore formation.   
The six-helix bundle formation of gp41 is believed to stabilize the pore on the target 
cell membrane.  When gp41 is in this stage, the fusion inhibitors that target N- and 
C-terminal heptad repeats are not able to bind to their targets. 
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New Anti-HIV-1 compounds 
 As it has been described earlier in this chapter, there is a constant need for new 
anti-HIV drugs.  This problem has been approached in many ways, from testing libraries 
of chemical compounds for anti-HIV activity, to the rational design of new inhibitors for 
different steps of the viral life cycle.  Part of my dissertation was to make new anti-HIV 
compounds using two approaches: 1) Linking two known anti-HIV compounds and 2) 
Testing for synergistic anti-HIV activity of known compounds. 
 Why would someone link two anti-HIV compounds?  There are many reasons: 
a) To increase the binding affinity of the chimeric compound to the target area.  If 
both compounds bind to their target area at the same time, it is possible that the 
overall binding affinity of the linked compound will be higher than each 
compound separately.  Higher binding affinity may correlate to higher anti-HIV 
activity (Figure I-9 A). 
b) To deliver one of the compounds near its binding area.  It is known that 
compounds, like C-terminal fusion inhibitor C37, bind unspecifically to the cell 
surface (73).  It is possible that linking two compounds, one being more specific 
than the other, will lead to better delivery of the not-so-specific compound to its 
binding area.  This delivery could lead to higher anti-HIV activity (Figure I-9 B). 
c) It is easier for a virus to evade one anti-HIV compound through mutations than 
two linked compounds.   
d) Properties of one anti-HIV compound could be beneficial for the other compound.  
For example, if one of the compounds can access its target area only when the 
viral spike is in an “open” form, it is logical to assume that linking this compound 
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with another compound that can induce this conformational change of the viral 
spike may lead to an improvement in anti-HIV potency of the chimeric compound 
(Figure I-9 A). 
 Another section of my dissertation investigates if particular anti-HIV compounds 
show synergy.  Synergy is when different anti-HIV compounds cooperate with each 
other so that the final anti-HIV potency of the mix is better than the additive effects of 
the two compounds.  Synergy is of particular interest for two main reasons: a) it can 
show the mechanism of action of the tested compounds and b) it can suggest medical 
protocols for drug administration in HIV patients.  
 The anti-HIV compounds that I used in my research were: Griffithsin, 
CD4M33C1F23, C-peptides and P2-RANTES, a variant of chemokine RANTES (58).  I 
linked Griffithsin with C37, CD4M33C1F23 with C37, and Griffithsin with 
CD4M33C1F23, and I studied the possible synergy between P2 RANTES and C-
peptide fusion inhibitor C37 and C34.  In the following paragraphs I will describe 
each compound separately. 
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Figure I-9:  Models of action of the chimeric proteins.   
A) Two compounds are bound at the same time to their target areas.  In this 
particular example CD4M33C1F23 and C37 are bound to gp120 and gp41, 
respectively.  CD4M33C1F23 can induce conformational changes to gp120, allowing 
access of C37 to gp41.  B)  One compound is delivering the not-so-specific compound 
near its target area.  In this case Griffithsin is linked with C37 (Griff37) and is 
delivering C37 to the top of the viral spike.  C37’s target is the N-terminal heptad 
repeat (NTR) of gp41 that is part of the viral spike. 
 
 
 
Griffithsin 
 Griffithsin is a lectin originally isolated from the red algal Griffithsia sp. (118).  It 
shows activity against multiple viruses like HIV, severe acute respiratory syndrome 
(SARS), Ebola and herpes simplex virus (194, 198).  It crystallizes as a domain-swapped 
dimer (198, 199) (Figure I-10).  The monomeric form has 121 amino acids and a 
molecular weight of 12,858 Da.  As a lectin it can bind sugars like glucose, galactose, 
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mannose, maltose and fucose (118).  The affinity of Griffithsin to mannose 
monosaccharide is 102.0 ± 13.0 µM and to 1→6α-mannobiose 83.3±17.5 µM, 
respectively, and these interactions are entropically driven (199).   
Griffithsin shows anti-HIV activity in a broad spectrum of HIV strains with an 
IC50 in the pM range and is currently in pre-clinical trials as a microbicide (194).  ELISA 
assays reveal that Griffithsin binds both envelope glycoproteins gp120 and gp41 probably 
by bindings to the complex mannose on the surface of these proteins, so it is proposed 
that Griffithsin is a fusion inhibitor interrupting the gp120 – CD4 interaction.   
Co-crystallization of Griffithsin with mannose or 1→6α-mannobiose unveils that 
the Griffithsin dimer forms an almost equilateral triangle of surface areas which binds 
three molecules of mannose.  The residues of Griffithsin that play an important role in the 
Griffithsin – mannose interaction according to the crystal structure are Tyr28, Asp30, 
Tyr68, Asp70, Tyr110 and Asp112 (198) (Figure I-11).   
We linked Griffithsin with C-peptide fusion inhibitor C37.  The original 
hypothesis was that Griffithsin will bring C37 on the viral spike near gp41 (Figure I-9 B).  
In this way, we could have inhibition by griffithsin as well as enhanced inhibition by C37 
binding gp41. 
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Figure I-10:  Domain-swapped dimer of Griffithsin.   
1→6α-mannobiose shown as balls 
 
 
 
 
Figure I-11:  Griffithsin structure with 1→6α-mannobiose.   
For simplicity only one molecule from the dimer is shown.  Red color indicates 
important residues for the interaction with 1→6α-mannobiose.  Blue: 1→6α-
mannobiose (PDB ID: 2HYQ)  
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CD4M33C1F23 
 In 1998, Kwong et al. published the structure of the HIV gp120 envelope 
glycoprotein in complex with soluble CD4 (sCD4) and Fab 17b (84).  By dissecting this 
structure it became obvious that at the sCD4 – gp120 interaction, 22 CD4 residues and 26 
gp120 residues made direct inter-atomic contacts.  At the sCD4 site all these contacts are 
concentrated in the span of 25 to 64. The most important residues of this group are Phe 
43 and Arg 59.  Phe 43 by itself accounts for 23% of the total contacts between sCD4 and 
gp120.  
 In 1999, Vita et al. used the scorpion scyllatoxin, a 31 aa peptide that is 
structurally similar to the CDR2-like loop of sCD4, and inserted mutations that made it 
similar to sCD4.  This produced the CD4M9 peptide that showed moderate anti-HIV 
activity (176).  Further development of this peptide produced the peptide CD4M33 with 
significantly better anti-HIV activity (109).  This peptide replaces the Phe at position 23 
with a biphenylalamine (Bip) residue and instead of Cysteine at position 1 there is a 
thiopropionic acid (Figure I-12).  CD4M33, like sCD4, can induce conformational 
changes to gp120, making gp41 accessible for C-peptides that block the formation of the 
six-helix bundle (109).   
The initial hypothesis was that if we linked C37 with CD4M33, the CD4M33 
would open the viral spike and deliver C37 to gp41 (Figure I-9 A).  In this way we hoped 
to have simultaneous binding of CD4M33 and C37 to their target areas.  As a small 
alteration, since CD4M33 has unnatural amino acids, we chose to make a chimera 
between CD4M33 and CD4M9 that we named CD4M33C1F23.  We expressed C37 linker 
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CD4M33C1F23 in E.coli, since every applicable drug needs to be easily produced.  
Sequences for the various peptides I discussed above are the following: 
scyllatoxin                 AFCNL RM CQLSCRSLGLLGKCIGD   K     CECVKH 
CD4M9                    Ac -CNL AR CQLRCKSLGLLGKCAGS  F     CACGP 
CD4M33                  Tpa - NL HF CQLRCKSLGLLGKCAGS  Bip  CACV 
CD4M33C1F23                  CNL HF CQLRCKSLGLLGKCAGS  F     CACV 
Red colored items in the CD4M9 sequence are the mutations that are the same in the 
sCD4 sequence. 
 
 
 
 
Figure I-12:  CD4M33 (yellow) - gp120 (green) interactions.   
Disulfide bonds are shown in blue, and red corresponds to the biphenylalamine 
(Bip) residue of CD4M33.  
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C-peptide fusion inhibitor C37 and C34 
 C37 and C34 are two overlapping peptides that come from the C-terminal heptad 
repeat sequence of gp41.  C37 is 3 aa longer than C34 at the N-terminus.  Both of these 
peptides show anti-HIV activity in the nM range and they are unstructured when in 
solution (14).  After the addition of N36, a peptide from the N-terminal heptad repeat of 
gp41, to a C34 solution in 1:1 ratio, the formation of antiparallel interacting helical 
structures is observed (95).  It is believed that the mechanism of action of these two 
peptides is by blocking the formation of the six-helix bundle of gp41, destabilizing the 
fusion pore on the target cell membrane and stopping the insertion of the viral capsid into 
the target cell cytoplasm.  The most famous C-peptide is T20 (enfuvirtide), which is 
currently in clinical use as one of the last lines of defense against HIV when other drugs 
fail.  In Figure I-13, the amino acid sequences of T20 and C37 are shown.  
 
 
 
 
Figure I-13:  T20 and C37 amino acid sequences. 
The overlapping amino acids are shown with red color.  
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P2-RANTES 
RANTES is a chemokine that binds to G-protein coupled receptors CCR1, CCR3, 
CCR4 and CCR5, and mediates activation and chemotaxis in a series of cells like T cells, 
macrophages, eosinophils and basophils (48).  RANTES has been found to block HIV 
through competition with envelope glycoprotein gp120 for binding with CCR5 
coreceptors (Figure I-6) (48).   
Hartley et al. used a phage display library of randomly mutated and extended N-
terminal RANTES and screened for improved anti-HIV activity.  Using this method they 
discovered FSPLSSQSS-RANTES, named P2-RANTES, which shows a nM range of 
anti-HIV activity in various assays (57).  P2-RANTES acts against HIV in two different 
ways: 1) it competes with viral glycoprotein gp120 for binding with CCR5 and b) 
internalizes CCR5.  Low CCR5 density negatively affects virus infectivity and increases 
the potency of T20 in blocking HIV (62, 147).  We hypothesized that since P2-RANTES 
causes internalization of CCR5, it may cause an increase in the anti-HIV potency of C-
peptide fusion inhibitors C37 and C34.  In Figure I-14 you can see the crystal structure of 
P2-RANTES that has been solve by our lab (73). 
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Figure I-14:  P2-RANTES structure. 
Red color indicates amino acids FSPLSSQSS that have been added onto the 
RANTES amino acid sequence. (PDB ID: 2VXW) 
 
 
 
CXCL8 (Interleukin-8) 
 The second chapter of this dissertation is focused on CXCL8 studies and is 
independent of HIV fusion inhibitors.  CXCL8 is a CXC chemokine that plays an 
important role in recruiting leukocytes to the sites of injury and bacterial infections 
(chemotaxis) (120).  It is also a contributor in many types of cancer and metastasis since 
increased expression of CXCL8 or CXCL8 receptors have been found in cancer cells and 
tumor-associated macrophages (179).   
CXCL8 binds and activates two G-protein coupled receptors (CXCR1 and 
CXCR2) (140).  Its monomeric form is the high affinity receptor ligand and the CXCL8 
N-loop is shown to be important for receptor binding (145). 
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 All chemokines have similar structures even if they share less than 20% of aa 
sequence similarity.  They can also dimerize in different ways.  CXCL8 forms a tight 
dimer using the β1 strand; on the other hand, CCL4 (MIP-1β) dimerizes using the N-
terminal area of the protein, in particular Pro8, Phe13 and the 40’s loop.  We suggest that 
evolutionary pressures kept chemokine structure very similar between different members 
of the family, while at the same time allowing changes in the ways its members 
dimerized.  Using a local sequence alignment of CCL4 related chemokines, we designed 
mutations to break the CXCL8 dimer, as described in detail in the Chapter IV.   
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CHAPTER II  
A POTENT STRATEGY TO INHIBIT HIV-1 BY BINDING BOTH gp120 AND gp41
 
Introduction 
 
About 2.7 million people are infected with HIV each year, and women comprise 
50% of the 33 million people living with AIDS (40).  In the developing world, effective 
prevention strategies are lacking, often because women have limited freedom in choosing 
sexual situations or in insisting on condom use.  Therefore, the development of an anti-
HIV microbicide is extremely important.  Properties that are desirable in a microbicide 
include the ability to effectively inhibit HIV infection at low concentrations, the ability to 
be applied topically on a regular basis without causing inflammation, stability to 
fluctuating temperatures, and inexpensive production.    
 The early events in an HIV-1 infection in T-cells can be described as follows.  
The HIV-1 envelope protein gp120 first makes contact with the human cell surface 
protein CD4, which causes conformational changes in gp120.  The gp120-CD4 
interaction facilitates the formation and exposure of the binding site on gp120 for its co-
receptor on the human cell, the chemokine receptor CCR5 (or CXCR4 in some strains) 
(41-44).  These HIV-cell interactions lead to the exposure of HIV-1 protein gp41, which 
mediates cell fusion.  Gp41 exists as a trimer having three major segments: The N-
terminal fusion peptide (FP) which inserts into the cell, the so-called N-terminal heptad 
repeat, and the C-terminal heptad repeat.  After the fusion peptide has inserted into the 
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cell membrane, the N-terminal segment and C-terminal segment come together to form a 
6 helix bundle, a trimer of hairpins (reviewed in (45,46)).  This action has the effect of 
pulling the viral membrane surface close to the cellular surface, facilitating the formation 
or stabilization of a viral pore.  It has recently been reported that these events may in part 
occur in the endosome: early binding events in cell fusion may occur at the cell surface, 
after which the entire complex is internalized into an endosome for the final fusion 
process (19).  
There are several strategies that have been shown to be successful in the 
inhibition of early events in HIV infection (entry inhibition).  Blocking the gp120-CD4 
binding interaction has been shown to be useful (47-49), and this is likely the interaction 
that is targeted by the alga-derived protein griffithsin (23).  Griffithsin is a leading 
candidate for a microbicide, having been shown to potently inhibit HIV infection (23,50), 
to be stable to warm temperatures and in the low pH environment of cervical fluid (50), 
and having recently been shown to be able to be produced in gram quantities from 
overexpression in plants (51).  The mechanism of action of griffithsin is likely based on 
its ability to bind the saccharides (particularly mannose) that cover the surface of both 
HIV gp120 and gp41.  In this regard, griffithsin has been shown to inhibit binding by 
gp120 to CD4 (23).  As evidence that the mechanism of this inhibition involves 
griffithsin binding to the glycosylated surface of gp120/gp41, exogenous addition of 
several types of individual saccharides has been shown to block the ability of griffithsin 
to inhibit HIV (23).  Also, griffithsin crystallizes in the presence of mannose (25), 
glucose and N-acetyl glucosamine (52), in each case revealing three saccharide binding 
sites per monomer.  A smaller molecule that is targeted to the gp120-CD4 interaction is 
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the designed peptide CD4M33. This 27 amino acid peptide has been shown to bind 
gp120 tightly, although micromolar concentrations are required to inhibit in cell-cell 
fusion assays using vaccinia technology (29).   
Another very effective anti-HIV strategy has been to inhibit the “trimer of 
hairpins” formation of gp41.  This has been effectively accomplished by peptides that 
bind to the helical regions of gp41, disallowing the full 6-helix bundle formation (45).  
The molecule T-20 is such a peptide that is derived from the C-terminal heptad repeat of 
gp41 (a “C-peptide”), thereby effectively binding the N-terminal region of the protein 
(31,53,54).  T-20 is currently in clinical use, and further work has also focused on the 
similar C-peptides C34 and C37, which are nearly identical to each other (differing by 
three extra amino acids at the N-terminus for C37) and that also bind to the N-terminal 
region of gp41 and prevent the 6 helix bundle formation that is critical for viral fusion 
(45,55-57).  
 We hypothesized that a single compound with the capability of interrupting both 
the gp120-CD4 interaction as well as the formation of the gp41 6-helix-bundle could 
have advantages for several reasons.  From a structural standpoint, the physical distance 
between target binding areas for linked compounds are not large since both gp120 and  
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gp41 are part of the same complex in the viral spike.  Functionally, a linked compound 
may improve binding affinity and/or specificity compared to its individual counterparts.  
Such a compound may have advantages in terms of the ability to target the virus under 
conditions of blood flow or in the milieu of a physiological environment.  Finally, an 
inhibitor comprising two separate strategies may provide comprehensive protection 
against multiple clades of virus even in the event of viral mutation. 
In the present study, we tested several linked compounds that encompass the 
strategy of binding both gp120 and gp41.  It was found that one compound, griffithsin-
linker-C37 (Griff37) is effective at lower concentrations than griffithsin alone or in 
combination with C37 (1:1) in cell-cell fusion assays and in viral assays, and that this 
inhibitor exhibits a great deal of specificity under conditions of wash-out and 
competition.  Overall, this and the other HIV inhibitors reported here may be useful as 
general anti-HIV therapeutics or, more specifically, as anti-HIV microbicides. 
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Experimental Procedures 
Protein production and purification 
Peptide fusion inhibitors N-acetylated, C-term amidated C37 and N-acetylated, C-
term amidated C37(Q652L) were obtained from Genescript (Piscataway, NJ).  The genes 
for GriffC37 and C37CD4M33C1F23 DNA were synthesized by Genscript.  All the 
constructs were placed into pET-15b (Novagen, Madison, WI). The amino acid sequence 
of CD4M33C1F23 is: CNLHF CQLRC KSLGL LGKCA GSFCA CV.  The amino acid 
sequence of the linker used for Griff37 as well as C37CD4M33C1F23 is: SSSGG GGSGG 
GSSSG S with minor variations between the different constructs due to cloning 
procedures.  The gene for griffithsin and Griff37 includes a 6 histidine affinity tag as well 
as a thrombin cleavage site, similar to that previously described (58).  The sequence for 
Griff37 (Griffithsin-linker-C37) is: MGGSS HHHHH HSSGL VPRGS LTHRK FGGSG 
GSPFS GLSSI  AVRSG SYLDA IIIDG VHHGG SGGNL SPTFT FGSGE YISNM 
TIRSG DYIDN ISFET NMGRR FGPYG GSGGS ANTLS NVKVI QINGS AGDYL 
DSLDI YYEQY SSSGG GGSGG GSSSG SHTTW MEWDR EINNY TSLIH SLIEE 
SQNQQ EKNEQ ELL. 
The sequence for C37CD4M33C1F23 is: MHHHH HHIEG RHTTW MEWDR EINNY 
TSLIH SLIEE SQNQQ EKNEQ ELLSS SGGGG SGGGG SSSSC NLHFC QLRCK 
SLGLL GKCAG SFCAC V. 
Griffithsin was expressed in BL21(DE3) (Novagen) E. coli cells in LB broth.  
Protein production was induced upon addition of IPTG to a final concentration of 1 mM, 
followed by incubation for 4 h at 37°C.  Pellets from these cells were resuspended in a 30 
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mL solution (500 mM NaCl, 20 mM Tris (pH 8), 10 mM benzamidine), then French 
pressed twice at 16,000 psi. After centrifugation for 1h at 17,000 g, the supernatant was 
loaded onto a Ni chelating column (Amersham Pharmacia Biotech) equilibrated with 50 
mM Tris (pH 8.0), 500 mM NaCl, and eluted with a gradient using 500 mM imidazole, 
50 mM Tris (pH 8.0), 500 mM NaCl.  The fractions containing purified protein were 
dialyzed in a buffer (20 mM Tris (pH 8.0)) at 4°C overnight.  The concentrated protein 
was further purified on a C4 reversed phase chromatography column (Vydac, Hesperia, 
CA), then lyophilized in a Labconco freeze dry system (Labconco Corporation).  For 
NMR and some functional studies, protein was produced in minimal media with 15NH4Cl 
as the sole nitrogen source, using the same purification procedure after production.  In 
early preparations, cleavage of the N-terminal Histidine tag at the thrombin site was 
attempted by incubation at room temperature in the presence of thrombin.  This cleavage 
was unsuccessful, so experiments proceeded in the presence of the His tag for griffithsin, 
Griff37, Griff37(Q652L), and GriffCD4M33C1F23,.  Others have shown that the presence 
of an N-terminal His tag does not affect the activity of griffithsin (23,58). 
Griff37 (which is griffithsin-linker-C37), Griff37(Q652L), GriffCD4M33C1F23 and 
C37CD4M33 C1F23 were expressed in BL21(DE3) either in LB media or minimal media 
as indicated above, although these proteins were found in the inclusion body.  Therefore, 
after induction for 4 hours upon addition of 1mM IPTG at 37oC, the cells were 
resuspended in 30 mL 5 M guanidinium chloride, 500 mM NaCl, 20 mM Tris (pH 8.0), 
then French pressed at 16,000 psi.  After centrifugation for 1 hour at 17,000 g to remove 
undissolved material, the supernatant was loaded onto a Ni chelating column (Amersham 
Pharmacia Biotech) equilibrated with 5M Guanidinium, 50 mM Tris (pH 8.0), 500 mM 
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NaCl).  Elution was carried out with 5M Guanidium, 500 mM imidazole, 50 mM Tris 
(pH 8.0), 500 mM NaCl.  Fractions containing purified protein were combined and -
mercaptoethanol was added to a final concentration of 10mM and incubated for 2h with 
slow stirring.  The protein was then dialyzed in 20 mM Tris (pH 8.0) at 4°C overnight 
and it was further purified as described above, with C4 reversed phase chromatography 
followed by lyophilization.  For C37CD4M33 C1F23, a further step of proteolytic cleavage 
of the His-tag by Factor Xa was added (reaction buffer: 50mM Tris-HCl, pH 7.5, 150mM 
NaCl, 1mM CaCl2).  Cleaved protein was finally purified with C4 reversed phase 
chromatography, and then lyophilized in a Labconco freeze dry system. 
The proteins were analyzed by mass spectrometry on an Agilent 1100 HPLC and 
Thermo Fisher LCQ ion trap mass spectrometer (Stanford University).  Expected values 
based on amino acid sequence are shown in parentheses after each experimental value.  
Griffithsin: 14552 (14554, assuming N-terminal Met cleavage); Griff37: broad peak at 
20544 (20519); Griff37(Q652L): 20259 (20504); C37CD4M33C1F23: 8696 (8709). 
Cell culture 
Seven cell lines were used:  
1) HeLa-ADA cells that stably expressed HIV-1 Env from the CCR5-tropic strain 
ADA were maintained in DMEM supplemented with 10 % FBS plus 2 µM 
methotrexate (Sigma) as a selective reagent.  This cell line was a kind gift from 
Dr. M. Alizon and Dr. Anne Brelot (Cochin Institute, Paris, France) (59). 
2) HeLa-P5L cells that stably expressed human receptors CD4 and CCR5 were 
maintained in RPMI-1640 supplemented with 10 % FBS plus 0.5 mg/ml  zeocin 
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(Invitrogen) for selection of CCR5 expression.  They were a kind gift from Dr. M. 
Alizon and Dr. Anne Brelot (Cochin Institute, Paris, France) (59).  
3) HeLa-TZM-bl cells that stably expressed human receptors CD4, CCR5 and 
CXCR4 were maintained in DMEM supplemented with 10 % FBS.  This cell line 
was obtained through the NIH AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH and was a gift to that program from Dr. John C. 
Kappes, Dr. Xiaoyun Wu and Tranzyme Inc (60-63).   
4) HL2/3 cells that stably expressed HIV-1 Env and Tat from the CXCR4-tropic 
strain HXB2 were obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH and were a gift to that program 
from Dr. Barbara K. Felber and Dr. George N. Pavlakis (64).  The cells were 
maintained in DMEM supplemented with 10 % FBS and 500 µg/mL G418. 
5) MAGI-CCR5 cells that stably expressed human CD4 and CCR5, naturally 
expressed CXCR4, and contain an HIV-1 LTR-β-galactosidase reporter gene 
construct were maintained in DMEM supplemented with 10% fetal bovine serum, 
100 U/mL penicillin, 100 µg/mL streptomycin, 300 µg/mL L-glutamine, 0.2 
mg/mL G418, 0.1 mg/mL hygromycin B and 1 µg/mL puromycin.  These cells 
were obtained through the NIH AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH and were a gift to that program from Dr. Julie 
Overbaugh (65). 
6) 293FT cells were maintained in DMEM supplemented with 10 % FBS and were a 
kind gift from Dr. Jennifer Manilay, originally obtained from Invitrogen 
(Carlsbad, CA). 
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7) Mouse 3T3 cells (a kind gift from Jean Phillipe Pellois, originally obtained from 
the American Tissue Type Collection (ATCC), were maintained in DMEM 
supplemented with 10 % FBS. 
In addition, fresh human PBMCs were isolated and used in antiviral assays as previously 
described (66,67).  
Virus isolates 
HIV-1 isolates were obtained from the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH as follows: HIV-1 Ba-L from Dr. 
Suzanne Gartner, Dr. Mikulas Popovic and Dr. Robert Gallo (68,69); HIV-1 Ada-M 
(referred to as HIV-1 ADA) from Dr. Howard Gendelman (70-73); HIV-1 92HT599 from 
Dr. Neal Halsey and the DAIDS, NIAID; HIV-1 IIIB from Dr. Robert C. Gallo (74-76); 
HIV-1 91US005 from Dr. Beatrice Hahn and the DAIDS, NIAID and  pNL3-4 from Dr. 
Malcolm Martin(77).  HIV-1 Ba-L, 92HT599, NL4-3 and 91US005 were used for PBMC 
assays, while HIV-1 Ba-L, ADA, and IIIB were used for MAGI antiviral assays. 
Cell-cell fusion assay 
HIV-1 Envelope-mediated cell-cell fusion assays have already been described 
(59).  Briefly, for the CCR5-tropic fusion assay, 104 HeLa-P5L cells (target) per well 
were seeded in a 96 well plate.  After ~12 hours, media was replaced with 50 µL RPMI-
1640.  Serial dilutions of inhibitor were added to the wells of the plate: 20 µL of protein 
or peptide was added to the first well and mixed, then 20 µL was removed and added to 
the next well and so on.  104 HeLa-ADA cells (effector) in 50 µL RPMI-1640 were then 
added to each well (100 µL media per well total).  The cells were allowed to fuse for 24 
hours at 37oC.  Cells were then lysed by adding 0.5% NP-40 (US Biological) in PBS for 
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30min, then assayed for β-galactosidase activity after addition of 8 mM substrate CPRG 
(chlorphenol red-β-D-galactopyranoside, Calbiochem) in PBS with 20 mM KCl and 10 
mM β-mercaptoethanol (Sigma).  The absorbance at 570 nm (signal) divided by 630nm 
(background) was measured.  The percentage of cell-cell fusion was calculated as [100 x 
(mean absorbance of treated well - mean absorbance of HeLa-P5L-only well)] / (mean 
absorbance of untreated well – mean absorbance of HeLa-P5L-only well).  The “treated” 
wells contained inhibitor while “untreated” wells contained effector cells plus target cells 
in the absence of inhibitor.  Kaleidagraph (Synergy Software, Reading PA) was used to 
fit the data into a four-parameter logistic equation.  P-values were obtained using an 
unpaired, 2-tailed student’s t-Test in Microsoft Excel.  Supplemental Tables show more 
comparisons by this method.  
In the CXCR4-tropic fusion assay, HeLa-TZM-bl cells were used as target cells 
and HL2/3 cells were used as effector cells.  The rest of the procedure was identical to the 
CCR5-tropic fusion assay. 
 In the competition CCR5-tropic fusion assay, 5x103 HeLa-P5L cells were seeded 
together with 5x103 3T3 cells per well.  The rest of the procedure was identical to the 
normal CCR5-tropic fusion assay.  
In the low temperature CCR5-tropic fusion assay, the addition of effector cells to 
target cells was immediately followed by 2 hours of incubation at 16oC.  The plate was 
returned afterwards to the 37oC cell incubator for 24 hours.  
In the wash-out assay, HeLa-ADA or HeLa-P5L cells were seeded in a 96 well 
plate the day before the assay.  After the formation of the inhibitor gradient by serial 
dilution, as described above, the cells remained at room temperature for 30 min.  
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Afterwards, the media containing inhibitor was removed and every well was washed with 
PBS twice.  New media without inhibitor was added and the complementary cell (HeLa-
P5L cells or HeLa-ADA cells) were seeded in the plate. 
Single round infection assay 
HIV virions deleted in vpr and env were used to make single round infectious 
particles as follows.  Plasmid pNL-luc3-R-E- containing the firefly luciferase gene, pSV-
ADA(R5) and pSV-JRFL(R5) were kind gifts from Dr. Nathaniel Landau (78).  For virus 
production, 293FT cells were doubly transfected with pNL-luc3-R-E- and either pSV-
ADA or pSV-JRFL plasmids according to the product manual (ProFection Mammalian 
Transfection System (Promega)).  48 hours post-transfection, the supernatant was 
harvested, centrifuged at low speed, and filtered with a 0.45 um syringe filter.  This viral 
stock was stored at -80 oC.  For the assay, 104 TZM-bl cells per well were seeded in a 96 
well plate.  The next day, the media was removed and replaced with 50 µL of new media. 
Serial dilutions of inhibitor were carried out in the wells of the plate: 20 µL of protein or 
peptide was added to the first well and mixed, then 20 µL was removed and added to the 
next well and so on.  Virus was added in an amount to obtain a luciferase signal between 
60,000-80,000 arbitrary units for the ADA-env pseudo virus (while the control of non-
infected cells gave ~600 arbitrary units) and 40,000-60,000 arbitrary units for the JR-FL-
env pseudo virus.  The total volume of media per well after pseudo virus addition was 
100 µL.  After 24 hours, old media was removed and replaced with new media.  A further 
24 hours later, the media was removed and the cells were lysed using Glo lysis Buffer 
(Promega) according to the manual.  Luciferase substrate was then added (Luciferase 
Assay System (Promega)) and the plate was read using an Orion II microplate 
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luminometer (Berthold Techniques, Germany).  The percentage of viral infection was 
calculated as [100 x (mean absorbance of treated well– mean absorbance of TZM-only 
well)] / (mean absorbance of viral infection in the absence of inhibitor – mean absorbance 
of TZM-only well).  The results were plotted using Microsoft Excel, and the IC50 and 
IC90 were calculated using a linear equation fitted between two experimental points 
surrounding the IC50 or IC90. 
MAGI antiviral assays 
 The CCR5- and CXCR4-tropic MAGI antiviral assays were both performed using 
MAGI-CCR5 cells in a manner identical to the CCR5-tropic HIV-1 entry assay described 
previously (67), with the exception that the virus and test compounds were left in the 
culture for the entire 48 hour incubation period, compared to washing out of virus and 
test compound 3 hours post-infection for the HIV-1 entry assay.   
HIV-1 strains Ba-L and ADA were used for the CCR5-tropic assays, and HIV-1 
strain IIIB was used for the CXCR4-tropic assays.  Co-receptor dependence for each of 
the viruses used to infect MAGI-CCR5 cells, which express both CCR5 and CXCR4, was 
verified through the use of AMD3100 (CXCR4 inhibitor; positive control inhibitor for 
IIIB, and negative control inhibitor for Ba-L and ADA) and TAK779 (CCR5 inhibitor; 
positive control inhibitor for Ba-L and ADA, and negative control inhibitor for IIIB) as 
control compounds (data not shown).  Data processing was performed in a similar 
manner as described above for the single round infection assay. 
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NMR spectroscopy 
 Samples that were isotopically labeled with 15N were prepared by growing 
BL21(DE3) containing the expression vector pET-15b in the presence of minimal 
medium containing 15NH4Cl as the sole nitrogen source as described above.  Samples 
were dissolved in 20 mM sodium phosphate buffer pH 7.0 with 5% D2O and a small 
amount of DSS (2,2-dimethyl-2-silapentane-5-sulfonate) for spectral referencing (79). 
The samples were placed in Shigemi tubes (Allison Park, PA).  Spectra were measured at 
25 °C on a four-channel 600 MHz Bruker Avance III spectrometer equipped with a 
GRASP II gradient accessory and a TCI cryoprobe, which has an actively-shielded Z-
gradient coil and cooled preamplifiers for 13C, 1H, and 2H.  1H-15N correlation spectra 
were measured with 760* points in the 1H dimension and 64* points in the 15N 
dimension, were processed using the program nmrPipe, and visualized using nmrDraw 
(80).  
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Results 
Strategically linked compounds are potent in R5-tropic cell-cell fusion assays 
 We hypothesized that linking a gp120 binding protein with a gp41-binding 
protein could lead to an even more potent compound because potentially both gp120 and 
gp41 could be blocked from mediating the viral entry process.  As a test of this 
hypothesis, the potent HIV entry inhibitor, griffithsin, was covalently linked via a 16 
amino acid peptide linker with the gp41 binding peptide C37 to form “Griff37”.  Cell-cell 
fusion assays represent a common method of determining the antiviral potency of many 
compounds.  In this technique, HeLa cells presenting human proteins CD4, CCR5 and/or 
CXCR4 on their surface (target cells) are combined with HeLa cells presenting HIV-1 
Env proteins gp120 and gp41 on their surface and HIV-1 Tat in their cytoplasm (effector 
cells).  The cells fuse by interaction of their respective surface proteins in an event that 
generally mimics the HIV entry process.  The extent of cell-cell fusion can be measured 
using a reporter assay, because β-lactamase in the target cells is expressed under the 
control of the HIV-1 LTR promoter, which is activated by Tat from the effector cell upon 
fusion (59).   
 The results of CCR5-tropic cell-cell fusion assays are shown in Figure II-1 and 
Table II-1.  Griffithsin alone performs well, with an IC50 of 1.31 nM ± 0.87, and the 
C-peptide C37 has an IC50 of 18.2 ± 7.5 nM in this assay.  The two proteins in 
combination without being linked inhibit quite well, exhibiting an IC50 of 0.46 nM (for 
each protein, for a total concentration of 0.91 nM at 50% inhibition).  However, when the 
griffithsin and C37 are covalently joined by a 16 amino acid linker to form Grft-linker-
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C37 (hereafter referred to as Griff37), the effectiveness of the compound in the fusion 
assay increases dramatically, giving an IC50 of 0.15 ± 0.05 nM (Figure II-1A, 1B, Table 
II-1), which 8.7-fold greater than griffithsin alone.  It has been reported that the activity 
of C-peptides can be enhanced by making the point mutation Q652L (81), so this point 
mutation was made in the linked compound.  Griff37Q652L was produced and purified, 
but in the CCR5-tropic fusion assay this compound has approximately the same 
effectiveness as Griff37 (Table II-1).   
As a further test of the overall strategy to link gp120 binding molecules with gp41 
binding molecules, the peptide C37 was linked with a 16 amino acid linker to a modified 
version of the peptide CD4M33, an HIV inhibitor that was designed to bind gp120 in a 
manner similar to the protein CD4 (82).  While the published peptide contains unnatural 
amino acids in positions 1 and 23, we replaced these with natural amino acids Cys and 
Phe respectively in order to allow expression in E. coli.  We will refer to this peptide as 
CD4M33C1F23.   
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In CCR5-tropic fusion assays, C37-linker-CD4M33C1F23 (C37CD4M33C1F23) 
exhibited an IC50 of 6.84 ± 2.9 nM (Figure II-1 and Table II-1).  This value is 
significantly lower than that for either component alone in cell-cell fusion assays, since 
C37 has an IC50 of 18.2 nM, and His-tag-containing CD4M33C1F23 was not an effective 
inhibitor even at our highest tested amount of 1.4 µM.  Published reports of CD4M33 
also describe that micromolar amounts of the peptide are required to inhibit CCR5-tropic 
fusion in a cell-cell fusion assay using vaccinia technology (82).  We also produced the 
compound Griffithsin–linker-CD4M33C1F23 (GriffCD4M33C1F23), which could provide 
two molecules that bind to gp120.  This compound performed reasonably well in CCR5-
tropic cell-cell fusion assays, with an IC50 of 3.47 ± 0.97 nM, but did not appear to have 
enhanced activity compared to the individual components of the molecule.  
These results suggest the possibility that combining a gp120 binding protein (such 
as Griffithsin or CD4M33) with a gp41 binding protein (such as C37) is a potent strategy 
for inhibition of CCR5-tropic HIV. 
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Figure II-1:  Cell-cell fusion assays.  
A.  Sample CCR5-tropic fusion assay using HeLa-ADA effector cells and HeLa-P5L 
CCR5-bearing target cells. 
B.  Histogram showing the IC50 of several HIV inhibitors in CCR5-tropic fusion 
assays:  1. Griffithsin (GRFT); 2.Griff37; 3. Griff37(Q652L); 4.Griffithsin + C37 
(1:1); 5. Griffithsin + C37 (Q652L) (1:1); 6. C37CD4M33C1F2; 7. GriffCD4M33C1F23; 
8. C37; 9. C37Q652L.  Each experiment was done at least 3 times in triplicate, and 
the results are presented as the average plus/minus the standard deviation.   
C. Sample CXCR4-tropic fusion assay using HL2/3 effector cells and TZM-bl 
CXCR4-bearing target cells.    
D.  Histogram showing the IC50 of several HIV inhibitors in CXCR4-tropic fusion 
assays.  1. Griffithsin; 2.Griff37; 3. Griff37(Q652L); 4.Griffithsin + C37 (1:1); 5. 
Griffithsin + C37 (Q652L) (1:1); 6. C37CD4M33C1F2; 7. GriffCD4M33C1F23; 8. C37.  
Each experiment was done at least 3 times in triplicate, and the results are 
presented as the average plus/minus the standard deviation. 
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Table II-1:  Inhibition of HIV env-mediated cell-cell fusion.  
IC50 values for cell-cell fusion assays under various conditions.  All combinations are 
reported as total protein concentration.  Each experiment was done in triplicate and 
repeated at least 3 times except where noted. Numbers in parentheses indicate the p-
value resulting from a t-Test of that compound in comparison to griffithsin + C37. 
N.D.: Not determined.  The peptide C37 is a product of chemical synthesis and is 
capped at both ends, with N-terminal acetylation and C-terminal amidation 
 
Compound CCR5-
tropic 
fusion 
assay 
CXCR4-
tropic 
fusion 
assay 
CCR5-
tropic 
fusion 
assay with 
competition 
CCR5-
tropic 
fusion 
assay with 
wash-out 
on HeLa-
P5L cells 
CCR5-
tropic 
fusion 
assay with 
wash-out 
on HeLa-
ADA cells 
 IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) 
Griffithsin 1.31 ± 0.87 
0.468 ± 
0.265 
1.73 ± 0.60 7.34 ± 3.58 4.28 ± 1.50 
Griff37 
0.148 ± 
0.052 
(2.98*10-5) 
0.088 ± 
0.033 
(0.046) 
0.369 ± 
0.034 
(0.000067) 
1.41 ± 0.75 
(0.0292) 
3.39  ± 
0.56 
(0.0588) 
Griffithsin + C37 
(1:1) 
0.911 ± 
0.367 
0.542 ± 
0.385 
1.04 ± 0.23 13.3 ± 7.3 6.23 ± 1.73 
Griff37 
(Q652L) 
0.121 ± 
0.056 
(7.70*10-6) 
0.167 ± 
0.085 
(0.0633) 
N.D. N.D. N.D. 
Griffithsin + 
C37(Q652L) (1:1) 
2.01 ± 0.66 1.35 ± 0.65 N.D. N.D. N.D. 
C37CD4M33C1F23
1 6.84 ± 2.85 2.30 ± 0.98 7.78 ± 1.56 561 ± 318 77.8 ± 1.2 
GriffCD4M33C1F23 
1 
3.47 ± 0.97 1.19 ± 0.44 12.6 ± 1.42 50.7  ± 9.0 N.D. 
C37 18.2 ± 7.5 2.70 ± 1.27 61.4 ± 7.9 
No 
inhibition 
No 
inhibition 
C37(Q652L) 28.2 ± 8.3 N.D. N.D. N.D. N.D. 
 
1.  CD4M33C1F23 is a recombinantly produced protein based upon the synthetically 
produced peptide CD4M33 designed by Martin et al (29).   
2.  This experiment was done in triplicate repeated two times.  
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Strategically linked compounds are potent in CXCR4-tropic cell-cell fusion assays 
 The linked combination of griffithsin and C37 was also quite potent in CXCR4-
tropic cell-cell fusion assays.  As shown in Figure II-1 and Table II-1, while griffithsin 
alone exhibited an IC50 of 0.47 ± 0.27 nM, the linked Griff37 was 5.3-fold more potent, 
similar to the point mutant of the linked compound, Griff37Q652L (Table II-1).  When 
unlinked, the combination of griffithsin and C37 were only slightly more potent than each 
separately (Figure II-1C, 1D and Table II-1).   
  When C37 was linked with the gp120-binding peptide CD4M33C1F23, the 
resulting C37CD4M33C1F23 gave an IC50 of 2.30 ± 0.98 nM.  Since this is close to the 
value of C37 alone, and CD4M33 has been shown to inhibit in a CXCR4-tropic fusion 
assay in the micromolar range  (IC50 of 0.8 ± 0.09 µM) (29), it appears that linking the 
two inhibitors in this case does not improve inhibition.  Interestingly, these results differ 
from the CCR5-tropic cell-cell fusion assay, where the C37CD4M33C1F23 compound 
gave an IC50 that was significantly better than either compound alone (Figure II-1 and 
Table II-1).  
Strategically linked compounds perform well in viral and pseudoviral assays 
To confirm that the strategy of linking a gp120-binding protein with a gp41-
binding peptide is successful in inhibiting HIV replication, a series of assays were 
performed using several types of target cells and viral strains.  In replication competent 
HIV assays, the linked compound Griff37 consistently performs better than griffithsin 
alone.  For example, when the CCR5-tropic HIV-1 strain Ba-L is used to infect MAGI 
cells, griffithsin alone exhibits an IC50 of 0.04 ± 0.01 nM, while Griff37 is 2.7-fold better, 
with an IC50 of 0.015 ± 0.005 nM (Table II-2, Figure II-2) and the unlinked combination 
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of griffithsin and C37 has an IC50 of 0.05 nM in each protein.  Similarly, when the CCR5-
tropic HIV-1 strain ADA infects MAGI cells, Griff37 is 2-fold better than griffithsin 
alone and 6.3-fold better than the unlinked combination of griffithsin and C37 (total 
protein concentration) (Table II-2).  The effect in most cases is even more dramatic when 
comparing concentration at 90% inhibition (IC90) for these compounds against viral 
strains:  For Ba-L, Griff37 is 6.4-fold more potent than Griffithsin and 9.4-fold more 
effective than the unlinked combination (Table II-2); similar results are observed for 
inhibition of strain ADA.    
As described for fusion assays, these compounds are also highly effective against 
CXCR4-tropic HIV strains.  When MAGI cells are infected by the CXCR4-tropic strain 
HIV-1 IIIB, Griff37 again shows several-fold higher potency than its components (Table 
II-2). 
   
 
Figure II-2:  HIV viral assays.  
ADA and Ba-L virus strains were used to infect MAGI cells. Griff37 (both lines 
nearly overlapping) performs better than griffithsin in both cases. 
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Table II-2:  Inhibition of HIV-1 replication in MAGI cells. 
IC50 and IC90 values for viral replication assays.  All combinations are reported as 
total protein concentration.  Numbers in parentheses indicate the p-value resulting 
from a t-Test of that compound in comparison to Griffithsin + C37.  Each 
experiment was done in triplicate and repeated 2 times.   
 
Compound Ba-L (CCR5-tropic)  ADA (CCR5-tropic)  IIIB (CXCR4-tropic)  
 IC50 nM IC90 nM IC50 nM IC90 nM IC50 nM IC90 nM 
Griffithsin 
0.040 ± 
0.010 
0.515 ± 
0.055 
0.030 ± 
0.010 
0.450 ± 
0.040 
0.145 ± 
0.065 
0.890 ± 
0.110 
C371 
7.56 ± 
1.07 
79.7 ± 2.5 
6.15 ± 
1.40 
68.9 ± 4.2 10.3 ± 1.9 > 100 
Griffithsin 
+ C37 (1:1) 
0.100 ± 
0.030 
0.750 ± 
0.020 
0.095 ± 
0.015 
0.705 ± 
0.005 
0.230 ± 
0.020 
2.21 ± 
0.57 
Griff37 
0.015 ± 
0.005 
(0.1077) 
0.080 ± 
0.010 
(0.0011) 
0.015 ± 
0.005 
(0.037) 
0.085 ± 
0.005 
(0.00013) 
0.035 ± 
0.005 
(0.011) 
0.325 ± 
0.065 
(0.081) 
 
 
 
Similar results are observed when human PBMCs are infected with HIV-1 Ba-L.  
In this case, griffithsin alone has an IC50 of 0.28 ± 0.17 nM, while Griff37 is 4.7-fold 
better, with an IC50 of 0.059 ± 0.0004 nM, and the unlinked components griffithsin plus 
C37 are less than two-fold better than griffithsin alone (Table II-3).  When the CCR5-
tropic HIV-1 clinical isolate 91US005 is used to infect PBMCs, the result is about a two-
fold improvement for Griff37 over griffithsin alone (Table II-3). GriffC37 also shows a 
3.8-fold increase in anti-HIV potency compared to Griffithsin alone in CXCR4-tropic 
strains NL4-3 and 92HT599 (primary strain; Table II-3). Since the griffithsin-containing 
compounds were clearly more potent than the CD4M33C1F23 -containing compounds, the 
CD4M33C1F23 compounds were not tested in replication competent viral assays.  
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Table II-3:  Inhibition of HIV-1 replication in PBMCs. 
IC50 and IC90 values for viral replication assays.  All combinations are reported as 
total protein concentration.  Numbers in parentheses indicate the p-value resulting 
from a t-Test of that compound in comparison to Griffithsin + C37.  Each 
experiment was done in triplicate and repeated 2 times. 
 
 
 
 
 
In single-round infection assays griffithsin and its analogs all perform quite well.  
HIV virions pseudotyped with Env from the CCR5-tropic HIV-1 strains JR-FL or ADA 
were both used in inhibition assays.  While Griff37 performed better than griffithsin 
alone with strain JR-FL, it did not perform better using strain ADA (Table II-4).  Indeed, 
using strain ADA in a single round infection assay was the only instance we identified in 
which Griff37 was not superior to griffithsin (Table II-1, Table II-2,  
Table II-3, Table II-4). In addition, the combination of gp41 binding peptide C37 
with gp120-binding CD4M33C1F23, C37CD4M33C1F23, also appears to perform 
moderately better than the components CD4M33 (~2 fold) or C37 alone (~13 fold) in 
Compound 
Ba-L (CCR5-
tropic) 
91US005 
(CCR5-tropic) 
NL4-3 
(CXCR4-
tropic) 
92HT599 
(CXCR4-
tropic) 
 
IC50 
nM 
IC90 
nM 
IC50 
nM 
IC90 
nM 
IC50 
nM 
IC90 
nM 
IC50 
nM 
IC90 
nM 
Griffithsin 
0.280 
± 
0.170 
0.760 
± 
0.150 
0.280 
± 
0.170 
0.760 
± 
0.150 
0.170  
± 
0.040 
0.725 
± 
0.125 
0.74 ± 
0.37 
1.86 ± 
0.89 
C371 
2.39 ± 
0.635 
7.40 ± 
1.20 
2.39 ± 
0.635 
7.40 ± 
1.20 
2.89 ± 
0.39 
8.33 ± 
0.25 
14.5 ± 
1.4 
27.2 ± 
0.6 
Griffithsin 
+ C37 (1:1) 
0.33 ± 
0.05 
0.97 ± 
0.33 
0.33 ± 
0.05 
0.97 ± 
0.33 
0.220 
± 
0.040 
0.58 ± 
0.02 
0.76 ± 
0.24 
1.77 ± 
0.03 
Griff37 
0.059 
± 
0.0004 
(0.044) 
0.155 
± 
0.065 
(0.204) 
0.059 
± 
0.0004 
(0.077) 
0.155 
± 
0.065 
(0.155) 
0.045 
± 
0.005 
(0.049) 
0.205 
± 
0.035 
(0.011) 
0.195 
± 
0.025 
(0.144) 
0.630 
± 
0.070 
(0.004) 
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CCR5-tropic pseudoviral assays, although our CCR5 strains were not the same as those 
used by Martin (Table II-4 and (29)).  Again this indicates that the combination of a 
gp120-binding molecule with a gp41-binding molecule can be a potent HIV inhibition 
strategy, particularly since the CD4M33 component of our C37CD4M33C1F23 was not 
optimized for amino acid usage or foldedness during preparation. 
 
 
 
Table II-4:  Inhibition of HIV single round pseudovirus in TZM-bl cells. 
IC50 and IC90 values for single round pseudovirus assays.  Numbers in parentheses 
indicate the p-value resulting from a t-Test of that compound in comparison to 
griffithsin + C37.  Each experiment was done in triplicate and repeated at least 3 
times. N.D. : Not Determined 
 
Compound ADA (CCR5-tropic) JR-FL (CCR5-tropic) 
 IC50 (nM) IC90 (nM) IC50 (nM) IC90 (nM) 
Griffithsin 0.008 ± 0.016 0.164 ± 0.069 0.035 ± 0.008 1.25 ± 0.19 
Griff37 
0.020 ± 0.016 
(0.96) 
0.172 ± 0.061 
(0.12) 
0.025 ± 0.022 
(0.63) 
0.260 ± 0.101 
(0.0003) 
Griffithsin + C37 
(1:1) 
0.021 ± 0.018 0.277 ± 0.184 0.032 ± 0.017 1.38 ± 0.39 
Griff37(Q652L) 
0.023 ± 0.006 
(0.702) 
0.274 ± 0.066 
(0.52) 
N.D. N.D. 
Griffithsin + 
C37(Q652L) (1:1) 
0.021 ± 0.006 0.374 ± 0.192 N.D. N.D. 
C37CD4M33C1F23 2.33 ± 2.83 17.3 ± 17.4 2.25 ± 1.39 24.3 ± 19.6 
GriffCD4M33C1F23 0.222 ± 0.017 2.69 ± 0.23 0.270 ± 0.147 2.89 ± 0.25 
C37 27.2 ± 17.2 637 ± 290 15.2 ± 4.2 462 ± 357 
C37(Q652L) 114 ± 5 N.D. N.D. N.D. 
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Strategically linked compounds maintain effectiveness in competition assays and in 
 
washing assays  
 
 For a potential therapeutic to be beneficial in an organism, it needs to be able to 
effectively find its target in the milieu of other cell types and potential binding partners.  
As a test of this ability, the CCR5-tropic cell-cell fusion assay was modified with the 
addition of  fibroblast mouse 3T3 cells which are the most common cells at connective 
tissues.  These cells are not able to be infected by HIV and do not have human 
coreceptors on their surface, but they present a myriad of proteins and carbohydrates that 
could potentially bind an anti-HIV therapeutic and confound its ability to inhibit in the 
assay.  
 As we previously reported, in a CCR5-tropic fusion assay in the presence of 
unrelated competitor cells, the peptide C37 performs significantly worse than in the 
absence of such cells, with an IC50 of 61.4 ± 7.9 nM ((83) and Table II-1).  This leads to 
the possibility that Griff37 also performs worse in the presence of unrelated cells due to 
the presence of C37.  However, the linked compounds perform quite well under these 
conditions. The presence of competitor cells does not greatly affect griffithsin-containing 
compounds, as griffithsin alone still performs well.  But Griff37 again performs 
significantly better than griffithsin alone (Table II-1).  When C37 is linked to gp120-
binding peptide CD4M33 to make C37CD4M33C1F23, the resulting IC50 is 7.78 ± 1.6, 
which is close to the value in the absence of competition. Similar results were also 
observed for Griff37 in single round infection assays using virus pseudotyped with Env 
from the CCR5-tropic HIV-1 strain JR-FL in the presence of competitor cells.  In these 
experiments, all griffithsin-containing assays performed well, but Griff37 performed 
better than griffithsin alone (data not shown). 
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 To determine whether the linked inhibitors maintain some of their activity under 
conditions of washing out, modified R5 fusion assays were carried out.  In these assays, 
either the target cells or effector cells were placed in a well in the presence of inhibitor.  
The supernatant was then removed, cells were washed twice with PBS, and inhibitor-free 
media added, followed by the addition of the other cell type to allow fusion to proceed.  
Therefore, inhibition would only be observed for inhibitors that can maintain their 
presence rather than be washed away.  In these assays, an IC50 for C37 could not be 
determined because it was apparently fully washed out.  However, both griffithsin and 
Griff37 maintained nanomolar effectiveness when first bound to the ADA “HIV effector 
cells” before the washing step.  When the inhibitors were incubated with the target cell 
before the washing step, both inhibitors still performed well, but Griff37 was 5.2-fold 
more effective than griffithsin alone (Table II-1).  The fact that both griffithsin inhibitors 
retained some activity was somewhat unexpected since griffithsin should bind 
specifically to the HIV spike, which is not present on the target cells.  Indeed, griffithsin 
does demonstrate specificity by failing to block infection with HIV virions pseudotyped 
with SVA-MuLV (IC50 >100 (µg/ml) (51).  Possibly the washing conditions were too 
mild, as more vigorous washing does remove griffithsin inhibition (data not shown).  
Overall these experiments indicate that under physiological conditions where many 
different cell types and fluids may be present, these inhibitors maintain very high 
effectiveness, in contrast to C37 alone.    
 
 
 
48 
 
NMR experiments on the anti-HIV compounds 
Nuclear magnetic resonance (NMR) is a very effective technique for determining 
structural details of proteins, including their extent of foldedness and the possibilities for 
their oligomeric state (84-86).  Figure II-3A shows the 15N-1H correlation spectrum (15N 
HSQC) of griffithsin alone, which is a 121 amino acid protein that crystallizes as a dimer 
(25).  This type of spectrum shows one peak for every N-H pair in the protein, and 
therefore provides a fingerprint that is unique for each protein.  The spectrum of 
griffithsin shows good peak dispersion in the 1H dimension with well-resolved peaks, 
strongly suggesting a nicely folded protein, as would be expected for a stable, wild-type, 
relatively low molecular weight protein.   
Figure II-3B shows the spectrum of the linked compound Griff37.  Despite this 
protein exhibiting potent anti-HIV activity in numerous assays, the spectrum shows 
strong signal around 8.2 ppm in the 1H dimension, indicative of unfolded or random coil 
protein in the sample.  There are also peaks (of lower intensity) in the “folded” region of 
the spectrum (particularly above 9 ppm), and an overlay of this spectrum with griffithsin 
alone indicates that these peaks arise from folded griffithsin (overlay not shown).  There 
are several likely explanations for the poor quality of this spectrum despite the protein 
being quite active.  First, the 16 amino acid linker between griffithsin and C37 was 
designed to be structurally flexible, so the signal from this region is expected to resonate 
in the “unfolded” region of the spectrum.  Second, the peptide C37 is likely unfolded in 
the absence of a binding partner (87), which would lead to peaks in the unfolded region 
of the spectrum due to this peptide, even if the peptide would be fully active when 
presented with a binding partner in an assay.  Finally, if the Griff37 protein forms 
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oligomers or loose aggregates, line broadening would occur, which would have the effect 
of decreasing the intensity of all the peaks, particularly those from residues that are not 
free to move quickly in solution.  Therefore, a globular protein like griffithsin would be 
expected to lose a great deal of signal intensity upon oligomerization.  Overall, the 
spectrum of Griff37 suggests a sample that is at least partially folded (due to the clear 
presence of peaks that overlap with those in the griffithsin sample) but that may have a 
percentage of the sample unfolded and/or a portion of the sample in an oligomerized 
state.  
 NMR experiments were also carried out on the C37CD4M33C1F23 peptide 
combination.  Since this compound is a fusion of two peptides (albeit functionally active 
peptides), the unfolded peaks that are observed in the 8.2 ppm region of Figure II-3C 
were expected.  However, there were also peaks indicative of folded protein (several 
circled in Figure II-3C).  Since C34 (nearly identical to C37) has been shown to be 
unfolded in the absence of its gp41 binding partner (55), it is likely that the peaks in this 
region of the spectrum result from folded CD4M33C1F23.  The parent compound, 
CD4M33, was designed by Martin et al. to be a folded peptide containing unnatural 
amino acids and was produced for their work by chemical synthesis (29).  Therefore, it is 
notable that although we made multiple changes to CD4M33, including the use of 
“natural” amino acids to replace the designed unnatural amino acids, the use of 
recombinant expression rather than synthesis, and linkage with another peptide, the 
resulting protein still is an active anti-HIV compound that is at least partly folded. 
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Figure II-3:  15N-1H correlation spectra of some of the HIV inhibitors used in this 
study.   
A. Wild-type griffithsin. B. Griff37. C. C37CD4M33 C1F23.  Circled peaks on this 
spectrum indicate resonances that are consistent with folded protein.   
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Discussion 
 Many binding targets, both on the HIV-1 virion and on the human cell, have been 
established as effective sites for HIV inhibition.  But an underexplored area for HIV 
inhibition is to elucidate an overall strategy, possibly combining multiple inhibitors, that 
optimizes the effectiveness of inhibition under a number of different conditions and viral 
strains.  The present work examines the possible benefits of combining in a single 
compound both a gp120-binding and a gp41-binding moiety.  It was found that such a 
strategy consistently performs well both in cell-cell fusion assays and in viral assays, 
using both CCR5- and CXCR4-tropic strains, as well as under conditions of competition 
and washing out.  In most cases, the linked compounds performed better than their parent 
compounds, most strikingly in the case of improvement of the already highly potent 
protein griffithsin.   
Griffithsin has shown a great deal of promise in tests of its anti-HIV microbicidal 
characteristics.  In addition to remarkably high potency, it is stable upon incubation at 37 
°C, which is a necessary property if it must remain active in the human body for hours or 
be stored without refrigeration (50).  It also retains its activity in cervical/vaginal lavage 
fluid (50), is non-inflammatory in human cervical explants, is non irritating in a rabbit 
vaginal model and is active against multiple clades of HIV, indicating likely usefulness in 
many or all of the areas hardest hit by this disease (51).  
The most effective inhibitor in our experiments was Griff37, or possibly its slight 
variant Griff37Q652L, both compounds that covalently link griffithsin with the C-peptide 
C37.  This linked inhibitor performed at sub-nanomolar levels in both CCR5- and 
CXCR4-tropic fusion assays, and at mid-picomolar levels in viral assays.  These values 
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are in almost every case better than for griffithsin alone and better than an unlinked 
combination of griffithsin and C37 (Table II-1, Table II-2, Table II-3, Table II-4).  This 
indicates that the linked combination of inhibitors is indeed more potent that the 
individual components and worthy of strong consideration as a microbicide or 
therapeutic.  These effects are not likely due to synergistic action of the two inhibitors, 
because an examination of the combination index (an indicator of synergy; (88)) showed 
at best moderate synergy in fusion assays, while showing no synergy or even antagonism 
in viral assays (data not shown).   
In the replication competent viral assays, the improvement in the IC90 for the 
linked compound Griff37 was more statistically significant than the IC50 which is a 
positive indicator since 90% inhibition is perhaps more critical for truly stopping 
infection.  Statistical significance is judged by a comparison of the p-values derived from 
the student’s t-Test as described in Methods.  The Table II-5 also contains p-values for a 
comparison of the linked compounds with their unlinked controls for many types of assay 
presented here.  The greater effectiveness of Griff37 at the higher concentrations needed 
for 90% inhibition in the viral assay could be partly explained by the increasing 
importance of the C37 component at these concentrations because C37 inhibits at 
nanomolar levels.  As the concentration of the inhibitor rises from picomolar levels 
(where griffithsin binds to gp120), to nanomolar levels, the C-peptide may contribute 
more to the overall inhibition.  As a further test of the strategy of covalently linking a 
gp120-binding compound with a gp41-binding compound, the linked peptide 
C37CD4M33C1F23 was produced.  Again, this compound consistently showed more 
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potent inhibition than either component separately in the CCR5-tropic cell-cell fusion 
assay (Table II-1 and Table II-4).  
 
 
Table II-5:  t-Test P values for cell-cell fusion assay. 
a) Griffithsin vs Griff37 
CCR5 tropic 0.00020 
CXCR4 tropic 0.005143 
CCR5-tropic wash-out on HeLa-ADA cells 0.3933 
CCR5-tropic fusion assay with wash-out on HeLa-P5L 
cells 
0.0094 
CCR5-tropic fusion assay with competition 0.000187 
 
b) Griffithsin + C37 vs Griff37 
CCR5 tropic 2.98E-05 
CXCR4 tropic 0.046448 
CCR5-tropic fusion assay with wash-out on HeLa-
ADA cells 
0.0558 
CCR5-tropic fusion assay with wash-out on HeLa-P5L 
cells 
0.0292 
CCR5-tropic fusion assay with competition 0.000067 
 
c) Griffithsin vs Griff37(Q652L) 
CCR5 tropic 0.00053 
CXCR4 tropic 0.074787 
 
d) Griffithsin + C37(Q652L) vs Griff37(Q652L) 
CCR5 tropic 7.70E-06 
CXCR4 tropic 0.063342 
 
e) GriffCD4M33C1F23 vs C37 
CCR5 tropic 0.00265 
CXCR4 tropic 0.570381 
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 In deriving a set of possible models for the explanation of the effectiveness of 
Griff37, each model must account for the fact that this linked molecule is a significantly 
better inhibitor than the unlinked combination of the two components.  In keeping with 
this observation, there are at least three plausible models for the mechanism of action of 
Griff37.  The first model is that the griffithsin moiety binds to gp120 with high affinity, 
and the role of the linked C37 is simply to provide a more sizeable protein on gp120 
(Figure II-4A), making a more effective blockade against binding to CD4 or CCR5.  
However, arguing against this simple steric mechanism is the evidence that griffithsin 
linked to the peptide CD4M33 (Griff CD4M33C1F23) also would be expected to be able to 
provide a similar binding blockade, and yet this molecule does not show enhanced 
inhibition compared to griffithsin alone.  A second model is one in which the griffithsin 
component binds to gp120, thereby delivering C37 close to its binding site on gp41.  By 
being in physical proximity to gp41, C37 is able to bind gp41 and inhibit fusion if and 
when gp41 is exposed, possibly dislodging the linked griffithsin at that time. In this 
scenario, it is assumed that only one component of the linked pair is binding to its site at 
any given time, although they may both be in an on-off equilibrium with their respective 
binding sites (Figure II-4B).    
In the third model of action for Griff37, both components (i.e. griffithsin and C37) 
are bound to their respective targets simultaneously.  The 16 amino acid linker used in 
Griff37 was designed to be flexible and to allow simultaneous binding of the two 
components even if the binding sites were fairly distant.  For example, an 8 amino acid 
extended chain in griffithsin spans about 24 Å, so a 16 amino acid linker could 
potentially allow binding at sites several tens of angstroms apart.  In the structure and 
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structural model provided by Chen et al. in their work on unliganded SIV gp120 (89), 
much of the surface of gp120 is close enough to gp41 to allow simultaneous binding of 
griffithsin and C37.  However, it has been shown that structural changes in gp120 to 
allow exposure of gp41 does not occur unless CD4 is bound, and the presence of 
griffithsin is very likely to stop the binding of gp120 to CD4 (23).  Therefore, a 
“simultaneous binding” model of Griff37 action could possibly include two scenarios.  In 
one scenario, griffithsin is bound to carbohydrates on gp120, but not in a correct position 
to abrogate CD4 binding, which allows gp120 to contact CD4 and expose gp41.  The 
linked C37 moiety of Griff37 can bind gp41 and in this case provides “rescue” for the 
ineffective inhibition of griffithsin (Figure II-4C).  Alternatively, the griffithsin of 
Griff37 may inhibit CD4 binding on the monomer of gp120 to which it is bound, but a 
neighboring gp120 of the trimer may contact CD4 and alter its conformation enough to 
expose the gp41 trimer (Figure II-4D).  In this case, both griffithsin and C37 in the linked 
molecule can effectively bind to their target sites. 
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Figure II-4:  Possible models of action of linked compound Griff37.   
A) The inhibitory action of the molecule is due to griffithsin binding to gp120, but 
extra steric blocking is provided by C37.  B) Inhibition is provided by either 
griffithsin or C37, but only one is properly bound to its target at any given time.  C) 
Griffithsin binds to the “wrong” area of gp120, allowing CD4-gp120 interaction.  
This leads to exposure of gp41, so the C37 portion of Griff37 interacts with gp41, 
leading to inhibition.  D) A CD4-gp120 interaction on one of the gp120 monomers 
allows partial opening of the spike so that griffithsin (bound to another gp120 
monomer on the same trimer) can deliver C37 to gp41. 
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Similarly to the results with Griff37, experiments reported here with linked 
peptides also indicates the beneficial effects of binding both gp120 and gp41, although E. 
coli production without optimization leads to the possibility that the effect could be 
stronger after improved refolding conditions are determined.  The compound 
C37CD4M33C1F23 inhibits in CCR5-tropic fusion assays much better than either 
component alone, indicating the effectiveness of binding both targets of these 
compounds, possibly at the same time.  Small differences in IC50 values between C37 and 
linked compound C37CD4M33 C1F23 in the CXCR4-tropic cell-cell fusion assay may be 
explained by a lower affinity of CD4M33 C1F23 for HXB2 Env.  The lack of a proper 
control in this case (CD4M33 C1F23 alone) is critical.  It should be noted that the values for 
our version of CD4M33C1F23 are expected to be significantly worse than the reported 
values for the CD4M33 peptide, since ours is fully recombinant without the benefit of 
selectively designed unnatural components.  Another important point is the high number 
of cysteines (6 total) that C37CD4M33 C1F23 has that could allow for potentially different 
combinations of S-S bonds leading to unfolded protein.  Even if C37CD4M33 C1F23 
shows several folded peaks in the NMR spectrum, it is not clear that any or all of the 
proper disulfide bonds are formed.  Therefore, it is possible that CD4M33 C1F23 does not 
have the proper folding to bind as tightly to gp120 as the chemically synthesized 
CD4M33. Even with these drawbacks, it is fairly easy and economical to produce 
C37CD4M33C1F23 , and its relatively small size makes it an attractive candidate for 
further improvement.   
 It is possible that there are additional benefits to the linked compounds aside from 
improved potency.  The C-peptide T-20 is clinically approved but suffers from the need 
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for frequent dosing due to a short lifetime of only hours in vivo (90).  It has been shown 
that linking the similar peptide C34 with albumin (a larger protein) allows for high 
detectable plasma concentrations of the linked compound in rats for days, suggesting that 
linking a C-peptide with a larger protein may delay renal clearance and/or susceptibility 
to protease degradation (90).  Our experiments involve the protein C37, which, like T-20, 
is derived from the sequence of gp41 and which is identical to C34 but has an additional 
3 amino acids on the N-terminus.  It is possible that Griff37 has an in vivo lifetime of 
several days due to its larger size, similar to albumin linked C34 (90).  In addition, a 
benefit of a drug with two different sites of action is the difficulty of viral escape, since 
viral mutations to escape from one of the linked inhibitors would be expected to have 
little or no effect on the other inhibitor.  
 Other groups have also investigated the strategy of linking HIV inhibitors in order 
to increase effectiveness.  One very effective linked compound is a CD4 antibody having 
each heavy chain extended with a gp-41-binding C-peptide.  This chimeric protein 
showed HIV inhibition with an IC50 as low as 14 pM (91,92). This group also produced 
another excellent compound by linking a CCR5 antibody with a C-peptide (93).  In both 
cases, the antibody was expressed having one C-peptide at the C-terminus of each heavy 
chain of the antibody, resulting in a ratio of 2:1 C-peptide: antibody.  While both of these 
chimeric compounds would likely be highly effective microbicides, they have the 
disadvantage of being produced in a mammalian cell system (HEK cells), which would 
make it difficult to produce gram-quantities of the inhibitor.  In our system, Griff37 was 
produced from E. coli in shaker flasks and could likely be produced in large quantities by 
fermentation or in a plant based expression system, both of which were recently shown to 
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be useful in making large quantities of functional griffithsin (51,58).  Another effective 
HIV inhibitor was produced by linking two domains from CD4 with a single chain 
variable region from the antibody 17b, which is known to interact with gp120 on a site 
near its CCR5-binding region.  This inhibitor was shown to be effective at nanomolar 
levels and was expressed by recombinant vaccinia virus (94).  A recent study of a gp120 
antibody in various monomeric/dimeric covalent configurations and a gp41 antibody in 
these configurations also showed the importance of multivalency in HIV inhibition (95).     
Structurally, many questions remain unanswered about the compounds in the 
present study.  Griffithsin consistently crystallizes as a dimer (25,26,52), which could 
imply that a linked compound may include two molecules of griffithsin and two 
molecules of C-peptide.  However, the concentrations used in the functional assays are 
orders of magnitude lower than those for structural studies, so it has not yet been 
determined if the griffithsin dimer is a consideration in the function of the compounds 
reported here.   
The 1H, 15N correlation spectrum of griffithsin alone shows a nicely dispersed set 
of peaks indicative of a fully folded protein (Figure II-3A). To our knowledge, this is the 
first NMR spectrum reported for griffithsin, although several high quality X-ray 
structures have been determined (25,26,52).  The benefit of NMR spectra is that 
comparisons can quickly and easily be made between variants of a protein without the 
need for a full structural determination if sequence assignments have been completed.  
Such work for griffithsin is ongoing.   
NMR spectra of the strategically linked compounds show some resonances to 
indicate that both Griff37 and C37CD4M33C1F23 are folded, although it is not clear what 
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percentage of each sample is folded. The strong resonances in the unfolded region could 
simply be due to the presence of disordered C37 peptide and linker, or could in addition 
have a significant component from unfolded (and presumably non-functional) protein.  In 
the latter case, small improvements to the refolding procedure may lead to significantly 
more potent inhibitors. 
The strategically linked compounds reported here show picomolar levels of 
activity in many assays, but may still be able to be improved.  For example, the C-peptide 
component may be able to be improved by capping the charged ends that occur naturally 
when a protein is expressed rather than synthesized (81).  In our hands, N-acetylated, C-
amidated C37 inhibits in the CCR5-tropic fusion assay with an IC50 of 18.2 nM, as 
reported above.  However, C37 without the terminal modifications inhibits with an IC50 
of >100 nM.  Therefore, it is possible that capping the C-terminal end of Griff37 and 
C37CD4M33C1F23 could increase the potency of these compounds.  In addition, others 
have reported further improvements in C-peptides that increase their potency (96), which 
may be able to be incorporated into the strategy presented here.    
This paper presents evidence that the strategy of linking a gp120 binding 
molecule with a gp41 binding molecule can lead to a compound that has greater anti-HIV 
activity than its individual components alone or in combination.  It was demonstrated that 
the highly potent microbicidal candidate griffithsin could be made even more potent 
using this strategy.   
In the next chapter, I will described the synergistic effect on HIV inhibition 
between P2-RANTES and C-peptides C34 and C37. 
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CHAPTER III  
SYNERGY BETWEEN P2-RANTES AND gp41 BINDING PEPTIDES IN CELL-
 
CELL FUSION ASSAYS
 
 
Introduction 
 
 In addition to the more established anti-HIV-1 strategies such as inhibition of 
protease or reverse transcriptase, viral entry inhibition has great potential in the fight 
against AIDS.  Entry inhibition entails stopping HIV-1 before it breaches the cell, either 
as a strategy to prevent infection altogether or to curtail infection of new cells in an HIV-
positive individual.  Several strategies have proven effective at HIV-1 entry inhibition 
either in vitro or in vivo: binding to viral surface proteins gp120 and gp41, binding to 
human cell surface receptor CD4, and binding to human cell surface co-receptors CCR5 
and CXCR4 (97-99).  In particular, the synthesized peptide T-20 is believed to act by 
binding to gp41 (100,101) and is currently in clinical use.  But several recent studies 
revealed that T-20 does not block the six-helix bundle pre-hairpin formation (31,97). 
Another peptide, C37, derived from C-terminus of gp41 (and nearly identical to the 
widely reported C-peptide C34 (10,31,56)) is also reported to have strong anti-HIV entry 
activity due to tightly binding to the gp41 N-terminal helices (56,102). 
 The potential for synergy between two entry inhibitors is important for two 
reasons.  First, the therapeutic dose of the drugs will be lowered.  Second, the ability of 
the virus to develop resistance to two agents at the same time is much less likely than for 
a single agent.  Several studies have established that synergy can occasionally be 
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observed when two fusion inhibitors are combined in a viral assay or in vitro fusion assay 
(103-109).  For example, some synergy is observed in the combination of CCR5 
antibodies with T-20 (103,105), the combination of  small molecular antagonists of 
coreceptors with T-20 (108,109), the combination of small molecular antagonists of 
CCR5 with CCR5 antibodies (103,105,107), and  the combination small molecular 
antagonists of CCR5 with chemokines (105,108).  A potent synergy was observed 
between PRO 542 (a fusion of CD4 and immunoglobulin containing multiple CD4 units) 
and T-20, in which the IC50 of each component was 0.84 nM and 1.3 nM, respectively, 
but in combination the IC50 was reduced to 0.039 nM and 0.35 nM, respectively in cell-
cell fusion assays (106).   
In this paper we report that synergy can also be observed when some CCR5 
ligands are combined with gp41 binding peptides C37 and/or C34.  In particular, a 
combination of the RANTES mutant P2-RANTES (33)  and C37 in a 1:1 ratio yields an 
IC50 of 2.12 nM in an R5 tropic cell-cell fusion assay, which represents a dose reduction 
for both components and could lead to more effective HIV inhibition at lower doses.  We 
also observe moderate synergy at 90% inhibition in various viral assays.  
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Experimental Procedures 
Reagents  
All cell culture media and supplements and fetal bovine sera were purchased from 
Invitrogen (Carlsbad, CA).  The following were obtained through the NIH AIDS 
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: fusion 
inhibitor (N-acetylated derivative), the gene for HXB2-env (catalog number: 1069) from 
Dr. Kathleen Page and Dr. Dan Littman (110); the HeLa HL2/3 (64) cell line (containing 
genes from X4 strain HXB2) from Dr. Barbara K. Felber and Dr. George N. Pavlakis; the 
HeLa-TZM-bl cell line from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. 
(60,62,63); the mouse monoclonal antibody to human CCR5; mouse anti human CCR5 
monoclonal antibody from R&D Systems (catalog number: FABSP1, clone: 45502).  The 
HeLa cell line stably expressing HIV-1 ADA (R5) env (referred to as HeLa-ADA) was a 
kind gift from Dr. M. Alizon (Cochin Institute, Paris, France) (59). A HeLa cell line 
stably expressing human receptor CD4 and CCR5 (referred to as HeLa-P5L) was a kind 
gift from Dr. M. Alizon and Dr. Anne Brelot (Cochin Institute, Paris, France) (59).  The 
FITC (fluorescein isothiocyanate) labeled F(ab')2 fragment of polyclonal goat anti-mouse 
IgG secondary antibody was purchased from Sigma (catalog number: F 2653).  For C-
peptides, although they were successfully expressed and purified from E. coli, it was 
found that acetylation at the C-terminus and amidation at the N-terminus (such as can be 
obtained from commercial synthesis) resulted in higher activity.  Therefore, the peptides 
C37 and C34 (56) were obtained from Genescript company, and each was modified with 
acetylation at the C-terminus and amidation at the N-terminus.  These commercial 
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produced peptides were used in all assays except the FACS assays, which used E. coli-
produced C37. 
Protein production and purification 
 
For wild type chemokines RANTES protein expression and purification followed 
a standard chemokine refolding and purification method published previously (111-114).   
 The gene for the RANTES mutant, P2-RANTES, was amplified through standard 
thermocycling using the wild type RANTES as template (33), also adding the sequence 
for a Factor Xa cutting site upstream.  This was inserted into pET32-Xa (Novagen) at the 
NcoI - BamHI sites, and the DNA sequence of this mutant was confirmed through DNA 
sequencing. Upon expression, the protein has a 6 histidine tag and a thioredoxin fusion 
protein on the N-terminus to facilitate the purification.  When the fusion tag is removed 
(see below) the N-terminus of the P2-RANTES is exactly as published (33). 
For production of the protein P2-RANTES, a slight variation on the standard 
chemokine refolding procedure was used.  Protein production was induced by addition of 
IPTG to 1 mM in a culture of BL21(DE3) (Novagen) bearing the constructed plasmids, 
with shaking for 7 hours at 37ºC, and the cells were harvested by centrifugation at 6,000 
x g for 30 minutes.  The cells were resuspended in 30 mL of 500 mM NaCl, 20 mM Tris 
(pH 8), and 10 mM benzamidine and French pressed twice at 16,000 psi. After 
centrifugation for 30 minutes at 17,000 x g, the pellet was resuspended in 20 mL of 5 M 
guanidinium chloride, 50 mM Tris (pH 8), 500 mM NaCl.  The solution was stirred 
overnight and then centrifuged for 30 minutes at 17,000 x g to remove remaining 
insoluble pellet. The soluble denatured proteins were loaded onto a 5 mL chelating 
column (Amersham Pharmacia Biotech) equilibrated with the same buffer (5 M 
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guanidinium chloride, 50 mM Tris (pH 8), 500 mM NaCl).  The denatured proteins were 
purified through the chelating column using a gradient from 10% to 100% of 500 mM 
imidazole in 5 M guanidinium chloride, 50 mM Tris (pH 8), 500 mM NaCl.  The 
fractions containing purified denatured protein were pooled together and slowly shaken 
(50 rpm) for 2 hours at room temperature after adding β-mercaptoethanol to 10 mM.  The 
purified denatured proteins were dialyzed against 20 mM Tris-HCl, pH 8.0 overnight at 
4ºC.  After dialysis, precipitated matter was removed by centrifugation for 30 minutes at 
15,000 x g and the protein was purified on a C4 reversed phase chromatography column 
(Vydac, Hesperia, CA), and lyophilized by the Labconco freeze dry system (Labconco 
Corporation).  To remove the fusion tag, the protein powder was solubilized into ~1mL 
of 20 mM sodium phosphate (pH 2.5) and the volume was increased to ~ 40 mL in 20 
mM Tris (pH 8), 50mM NaCl, and 2 mM CaCl2.  Factor Xa (Novagen) was used for the 
proteolytic cleavage, which typically took 2 weeks at room temperature.  SDS-PAGE was 
used to monitor the cutting reaction.  Finally, the cut proteins were purified over a C4 
reversed phase chromatography column and lyophilized into powder.  
 For FACS assays, E. coli-produced C37 was used.  Since C37 does not interact 
with cell surface receptor CCR5, it is not expected that this peptide will provide different 
results than if commercially produced peptides were used.  For the C37 peptide, its 
corresponding gene (56) was amplified through standard thermocycling using the gene of 
HIV (HXB2) env as template, adding the sequence of a Factor Xa protease site upstream.  
The PCR product was placed into pET15b (Novagen, Madison, WI) at the Nde I-BamH I 
sites, and the DNA sequence of this mutant was confirmed through DNA sequencing.  
When it is expressed, the protein has a 6 histidine tag on the N-terminus that is 
66 
 
subsequently cleaved.  The purification of this peptide is the same as described for P2-
RANTES above. 
Cell culture  
 
The HeLa cell line stably expressing HIV-1 ADA (R5) env (referred to as HeLa-
ADA) (59) was cultured in DMEM supplemented with 10 % FBS, and 100 units of 
penicillin and 0.1 mg/ml of streptomycin and the ADA (R5) env was selectively 
expressed by adding 2 µM methotrexate (Sigma) as previously published (33,59,115).  A 
HeLa cell line stably expressing human receptor CD4 and CCR5 (referred to as HeLa-
P5L) (59) was cultured in RPMI-1640 (Invitrogen) supplemented with 10 % FBS, and 
100 units of penicillin and 0.1 mg/ml streptomycin. The expression of CCR5 was 
selectively expressed by adding zeocin (Invitrogen) 0.5 mg/ml.  The HeLa-TZM cell line 
was cultured in DMEM supplemented with 10% FBS, 100 units of penicillin and 0.1 
mg/ml of streptomycin as mentioned in the instructions provided by the NIH-ARRR. 
Cell-cell fusion assay  
 
Envelope-mediated cell fusion assays were carried out as described 
(33,59,115,116) with HeLa-P5L and HeLa-ADA cell lines (33,59,115,116), with minor 
modification.  Briefly, 104 HeLa-P5L cells were seeded in a 96-well culture plate in 50 µl 
RPMI-1640 medium per well for 12 hours. The individual chemokine or the 
combinations of chemokines with C37 or C34 were added into the cell medium with 
serial dilution.  Protein concentration was quantified by measuring the absorbance of the 
concentrated stock solution at 280 nm using the extinction coefficient method published 
by Pace (117), followed by serial dilution, done on the day of the assay.  After the 
addition of the inhibitor, 50 µl HeLa-ADA (104 cells per well) in RPMI-1640 medium 
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were overlaid into the 96-well culture plate.  After a further 24 hours of incubation at 
37ºC for complete fusion, cells in the 96-well culture plate lysed by adding 0.5% NP-40 
(US Biological) in PBS for 30 min at room temperature and assayed for β-galactosidase 
activity by the addition of 8 mM substrate CRPG (chlorphenol red-β-D-
galactopyranoside, Calbiochem) in PBS with 20mM KCl and 10mM β-mercaptoethanol 
(Sigma) for 2 hours in the dark at room temperature.  The absorbance at 570 nm (signal) 
divided by 630nm (background) was measured.  The percentage of cell-cell fusion was 
calculated as [100 x (mean absorbance of treated well - mean absorbance of HeLa-P5L-
only well)] / (mean absorbance of untreated well – mean absorbance of HeLa-P5L-only 
well).  The “treated” wells contained inhibitor while “untreated” wells contained effector 
cells plus target cells in the absence of inhibitor. Essentially the same procedure was used 
for X4 fusion assays using the HL2/3 cell line.  Experiments were performed in triplicate, 
repeated at least two times.  Dose dependent inhibition curves were fitted with a four-
parameter logistic equation (118) using KaleidaGraph (version 3.6, Synergy Software).  
No cell toxicity was observed for any dose of the proteins used in the assay. 
MAGI antiviral assays 
 
 The CCR5- and CXCR4-tropic MAGI antiviral assays were both performed using 
MAGI-CCR5 cells in a manner identical to the CCR5-tropic HIV-1 entry assay described 
previously (67), with the exception that the virus and test compounds were left in the 
culture for the entire 48 hour incubation period, compared to washing out of virus and 
test compound 3 hours post-infection for the HIV-1 entry assay.   
HIV-1 strains Ba-L and ADA were used for the CCR5-tropic assays, and HIV-1 
strain IIIB was used for the CXCR4-tropic assays.  Co-receptor dependence for each of 
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the viruses used to infect MAGI-CCR5 cells, which express both CCR5 and CXCR4, was 
verified through the use of AMD3100 (CXCR4 inhibitor; positive control inhibitor for 
IIIB, and negative control inhibitor for Ba-L and ADA) and TAK779 (CCR5 inhibitor; 
positive control inhibitor for Ba-L and ADA, and negative control inhibitor for IIIB) as 
control compounds (data not shown).  Data processing was performed in a similar 
manner as described above for the single round infection assay. 
Evaluation of synergy  
 
Analysis of synergy, additivity or antagonism between chemokines and C37/C34 
was performed using fixed ratios of drug combinations in antiviral assays according to 
the median effect principle of Chou and Talalay (88).  Chemokines and C37/C34 were 
tested individually and in a fixed molar ratio combination over a range of serial dilutions.  
The Combination Index (CI), and the Dose Reduction Index (DRI) were calculated based 
on the published protocol from Chou (88) using Microsoft Excel.  Based on this analysis, 
the CI value reflects the nature of the interaction between the drugs. CI < 1 indicates 
synergy; CI = 1 indicates additivity; and CI > 1 indicates antagonism. The DRI is a 
measure of how much the dose of each drug in a synergistic combination is reduced at a 
given effect level compared with the dose for each drug alone. 
Statistical analysis 
 
The 50% inhibitory concentration for each individual molecule and combination 
in case of the fusion assay was determined using KaleidaGraph (version 3.6, Synergy 
Software) from a standard four-parameter logistic regression (118).  In the case of viral 
assay, the results were plotted using Microsoft Excel, and the IC50 and IC90 were 
calculated using a linear equation fitted between two experimental points surrounding the 
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IC50 or IC90. Each experiment was done in duplicate or triplicate.  Multiple IC50 or IC90 
values obtained in this way from several repeats were then averaged together to obtain 
the data in Table III-1, Table II-2 and Table III-3.  The error shown is the standard 
deviation of the averaged data.  The Student t-Test (using the program Microsoft Excel) 
was applied for P value estimations that compared the statistical significance of the 
inhibitory concentration of a given molecule alone versus in combination.   
FACS analysis 
 
HeLa-TZM cells (105) were incubated for 30 min at 37°C in culture medium 
containing various concentration of (0-100 nM) of drugs in 10x75mm culture tubes 
(Fisher Scientific).  After washing 4 times with 10 mL cold PBS, cells were incubated in 
300 µl of 500 µg/ml mouse anti-human CCR5 monoclonal antibody in PBS-0.5% BSA 
(Sigma), and kept on ice for 45 min.  The cells were then washed 3 times with cold PBS-
0.5% BSA and incubated in 300 µl of 50 µg/ml FITC labeled polyclonal goat anti-mouse 
antibody in PBS-0.5% BSA, and kept on ice for 30 min. 1 aliquot of untreated cells were 
incubated with PBS-BSA for 30 minutes followed by 3 washes and incubation with the 
FITC-labeled goat anti-mouse IgG as control.  Then the cells were washed 3 times with 
cold PBS-0.5% BSA and kept in PBS-0.5% BSA, and analyzed with a FACSCalibur (BD 
Biosciences, San Jose, CA) flow cytometer using CellQuest (BD Biosciences) acquisition 
software.  Cell viability was determined by staining with propidium iodide (PI) at 1µg/ml 
final concentration 1 minute prior to analysis.  FITC fluorescence was collected through a 
530/30 bandpass filter, and PI fluorescence through a 650LP filter.  List mode data were 
acquired on a minimum of 10,000 viable cells defined by a light scatter and lack of PI 
staining.  Data were analyzed using FlowJo (Tree Star, Inc., Ashland, OR).  First, a 
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region to define cells was set using a forward and side light scatter plot, and then viable 
(PI-negative) cells were determined by a plot of forward light scatter and PI fluorescence.  
Results are presented as histograms of FITC fluorescence. 
 For FACS analysis of surface CD4 on PBMC, IL-2-PHA stimulated PBM cells (1 
mL at 106 cells/mL) were incubated for 60 min at 37°C in culture medium containing two 
concentrations of drugs in 10 x 75mm culture tubes (BD Biosciences).  High dose tubes 
contained 25 nM C37, 10 nM P2-RANTES, and 6 nM mixtures of P2-RANTES-C37 at 
1:1 and 10:1; low dose tubes contained 3 nM, 1.25 nM, 1 nM and 1 nM, respectively.  
After washing 2 times with 3 mL PBS, and 1 time with 4°C staining buffer (1% FBS in 
PBS), the cells were incubated in 150 µl of staining buffer-10 µL FITC-labeled mouse 
anti-human CD4 monoclonal antibody (BD Cat. No. 555346), and kept on ice for 30 min 
in the dark.  Control cells were similarly treated using an irrelevant FITC-labeled mouse 
antibody (BD Cat. No. 554679).  The cells were then washed 3 times with cold staining 
buffer and fixed with 500 mL of paraformaldehyde fixing solution (1% 
paraformaldehyde in PBS).  The cells were analyzed with a LSR11 Special Order System 
(BD Biosciences, San Jose, CA) flow cytometer using FACSDiva (BD Biosciences) 
acquisition software.  Cell viability was determined by trypan-blue exclusion staining 
before drug treatment.  List mode data were acquired on a minimum of 10,000 viable 
cells defined by light scatter. F Gating was done on a population of untreated and 
unstained PBMC using a forward and side light scatter plot.  
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Results 
Cell-cell fusion assays 
The CC chemokines RANTES, MIP-1α and MIP-1β have been shown to inhibit 
infection by HIV-1, and this ability to block entry helped lead to the discovery of CCR5 
as the HIV-1 coreceptor (119-122).  In later years, however, it became clear that wild 
type chemokines were not as effective as some modified chemokines in HIV-1 inhibition 
(22).  As shown in Table III-1 RANTES is a weak fusion inhibitor in a standard in vitro 
fusion assay, with an IC50 of 940 nM.  Not surprisingly, RANTES and other CCR5 
ligands are not notably effective in viral assays ((22) and unpublished).  Upon 
combination of RANTES with gp41-binding peptide C37 (1:1 ratio), better inhibition of 
fusion is observed, with an IC50 of 51 nM total protein concentration Table III-1.  
Similarly, the combination of RANTES and fusion inhibitor peptide C34 (1:1 ratio) also 
shows better inhibition than RANTES alone, although the effect is not large, with an IC50 
of 60 nM total protein concentration.  This modest but repeatable effect was assessed 
using the combination index formula described by Chou and Talalay (88).  The 
combination index (CI) of a two drug combination can be used to study the interactions 
of two drugs, where a value of 1 indicates no synergy between the two drugs (that is, 
their effects are merely additive), and values lower than 1 indicate synergy, with values 
closer to zero indicating more synergy.  The combination of RANTES and C37 showed 
no synergy, with a CI value of 1.47, indicating that the two compounds were at best 
working additively (Table III-1).  Similarly, RANTES in combination with C34 showed 
no synergy, giving a CI value of 1.09. 
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Table III-1:  RANTES and P2-RANTES in combination with C37 and/or C34 
inhibits HIV-1 (ADA) env mediated cell–cell fusion.  
Inhibition of R5-tropic cell-cell fusion (104 HeLa-P5L cells and 104 HeLa-ADA cells 
per well) of individual fusion inhibitors and their combinations.  Results are 
reported as the average IC50 ± standard deviation.  Each experiment was done in 
triplicate, repeated at least three times. IC50 values of combinations are reported as 
total protein concentration.  All R5-tropic fusion assays used 104 HeLa-P5L cells 
and 104 HeLa-ADA cells per well.   P values are reported using the student’s t-Test.  
All protein combinations were equimolar.  CI is combination index, explained in 
Methods. 
 
 
 
Drugs 
Inhibitor 
one 
IC50, nM 
Inhibitor 
two 
IC50, nM 
Combination 
of First 
Inhibitor and 
Second 
Inhibitor, IC50, 
nM 
P-value 
Inhib1 
compared 
to combo, 
Inhib2 
compare to 
combo 
Combination 
Index 
at 50% 
inhibition 
P2-
RANTES/C37 
2.46±0.90  18.2±7.5 
 
2.13±0.65 
 
1.9*10-4, 
2.35*10-8 
0.52 
P2-
RANTES/C34 
2.46±0.90 29.1±7.3 2.41±0.88 2.3 * 10-8, 
0.0004 
0.55 
RANTES/C37 943±145 18.2±7.5 51.2±22.3 3.74*10-6, 
0.0007 
1.47 
 
RANTES/C34 943±145 29.1±7.3 59.9±14.6 0.001; 0.014 1.09 
 
 
 
The RANTES variant “P2-RANTES” was discovered by Hartley et al., who used 
phage selection of randomly N-terminally mutated RANTES to discover this analog that 
tightly binds CCR5 and internalizes the receptor with high efficiency (33).  P2-RANTES 
performs quite well in fusion assays, having an IC50 of 2.4 nM in our hands (Figure III-1, 
Figure III-2) and 0.6-0.9 nM as reported by Hartley (33).  However, in a 1:1 combination 
of P2-RANTES with C37, the IC50 of inhibition is 2.1 nM, which is 1.06 nM in each 
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component, giving a CI value of 0.52 and a dose reduction of 2.3 for P2-RANTES and a 
dose reduction of 19 for C37 (Figure III-2 and Table III-1).  This value indicates 
moderate synergy with good potential for dose reduction.  Similarly, the combination of 
P2-RANTES and C34 also resulted in good synergy and effectiveness, with a CI value of 
0.56, a dose reduction in P2-RANTES of 2, and a dose reduction in C34 of 24 (Figure 
III-2 and Table III-1).  As a control, fusion assays were carried out using HeLa HL2/3 
cells, bearing gp160 from HXB2 (an X4 strain).  In these experiments, C37 was effective 
at nanomolar concentrations (as expected for an inhibitor that binds gp41), P2-RANTES 
alone had no effect on fusion (as expected for a protein that binds CCR5), and the 
combination of C37 and P2-RANTES was no more effective than C37 alone (data not 
shown). 
To determine which ratio of P2-RANTES and C37 best inhibits HIV-1 fusion, 
ratios of 1:4, 1:9, and 9:1were also tested.  As shown in Figure III-2 and Table III-2, the 
ratio of P2-RANTES:C34 9:1 has an IC50 of 2.0 nM (combined protein concentration).  
The reduction in dose for these inhibitors is quite good: while the amount of P2-RANTES 
required for 50% inhibition in the combination is only about 1.3-fold less than when 
alone, the dose reduction for C34 is 146-fold less in combination compared to C34 alone.  
Each combination of P2-RANTES plus C-peptide resulted in a dose reduction in C-
peptide, and usually a dose reduction in P2-RANTES as well (Table III-2). 
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HIV-1 infection assays 
 
The combination of P2-RANTES and C37 in a ratio of 1:1 was tested for 
inhibitory capacity against different strains of HIV-1 in both MAGI and PBMC cells.  As 
shown in Figure III-3 and Table II-2, P2-RANTES and C37 were each effective 
inhibitors, as reported previously (31,33,123).  The combination of P2-RANTES and C37 
(1:1 ratio) gives an IC50 of 1.67 nM (total protein concentration), and results in a CI of 
0.4 (Table III-2) for the Ba-L HIV strain in PBMCs cells.  P2-RANTES inhibits the 
replication of the HIV Ba-L strain in MAGI cells with an IC50 of 0.27 nM and IC90 of 5.7 
nM.  C37 inhibits HIV replication in the same strain at 6 nM and 85 nM respectively.  
These two drugs combined give an IC50 of 0.53 nM and an IC90 of 0.7 nM. The 
combination of P2 RANTES and C37 shows moderate synergy with 90% inhibition and a 
CI of 0.70.  At 50% inhibition these two drugs act additively.  HIV-1 ADA strains in 
MAGI cells show very similar results compared to the Ba-L strain in the same cells 
(Table III-3). 
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Figure III-1:  CCR5-tropic cell fusion assay.  
The error bars represent the standard deviation of more than 3 independent 
experiments.  To underline the synergy effect the P2-RANTES:C37 and P2-
RANTES:C34 assays have been plotted using the only concentration of P2-RANTES 
(not the combine compounds concentration) so the inhibition curves of the 
combined proteins are directly comparable with the control P2-RANTES. 
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Figure III-2:  CCR5-tropic cell fusion assay.  
It has been used to evaluate the anti-HIV potency of different compounds and 
combination of them at different ratio.  The IC50 of all the ratios describe total drug 
concentrations.  P2: P2-RANTES 
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Table III-2:  Varying molar ratios of P2-RANTES with C37/C34 inhibit HIV-1 
(ADA) env mediated cell–cell fusion.   
Inhibition of R5-tropic cell-cell fusion (104 HeLa-P5L cells and 104 HeLa-ADA cells 
per well) by various molar ratios of P2-RANTES and C37/C34.  Inhibitory 
concentrations are for each individual component of the combination.  Values are 
shown ± the standard deviation.  CI is the combination index; DRI is dose reduction 
index, which is the ratio of the amount of that protein alone needed to obtain 50% 
inhibition divided by the amount needed in combination. 
 
 
 
 
Ratio 
of 
P2-
RANTES 
: 
C37/C34 
at 50% 
Inhib. 
P2-RANTES 
concentration 
(nM) 
C37 / C34 
concentration 
(nM) 
CI at 
50% 
inhib. 
Dose 
reduction 
for 
P2-
RANTES 
Dose 
reduction 
for C37/ 
C34 
 alone conc 
P2-
RANTES 
in combo 
alone conc 
C37 
/ 
C34 in 
combo 
   
1:4 (C37) 2.46 
±0.90 
0.49 
±0.18 
18.17 
±7.46 
14.54 
±5.97 
0.81 2.15 4.63 
1:4 (C34) 2.46 
±0.90 
0.49 
±0.18 
29.10 
±7.31 
23.28 
±5.85 
0.68 2.15 6.50 
1:9 (C37) 2.46 
±0.90 
0.25 ±0.09 18.17 
±7.46 
16.35 
±6.71 
0.80 3.15 3.02 
1:9 (C34) 2.46 
±0.90 
0.25± 0.09 29.10 
±7.31 
26.19 
±8.12 
0.68 2.90 3.91 
9:1 (C37) 2.46 
±0.90 
2.21 
±0.81 
18.17 
±7.46 
1.87 
±0.75 
0.94 1.07 82.8 
9:1 (C34) 2.46 
±0.90 
2.21 
±0.81 
29.10 
±7.31 
2.91 
±2.1 
0.76 1.31 143.1 
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Figure III-3:  HIV-1 infection assay.   
ADA and Ba-L virus strains were used to infect MAGI cells.  P2-RANTES : C37 
(1:1) is plotted as a total concentration and the error bars represent the standard 
error of two independent experiments. 
  
 
Table III-3:  Inhibition of HIV-1 replication.   
Inhibition in an HIV-1 infection assay in the presence of the inhibitors P2-RANTES 
and C37 in a 1:1 ratio.  CI: combination index for a given percent inhibition. N.D.: 
Non determine 
 
Compound Ba-L (CCR5-
tropic) in 
MAGI cells 
ADA (CCR5-
tropic) in 
MAGI cells 
IIIB (CXCR4-
tropic) in MAGI 
cells 
Ba-L (CCR5-
tropic) in 
PBMCs 
 
IC50 
nM 
IC90 
nM 
IC50 
nM 
IC90 
nM 
IC50 
nM 
IC90 
nM 
IC50 
nM 
IC90 
nM 
P2-RANTES 
0.27 ± 
0.04 
5.68 ± 
1.13 
0.10 ± 
0.08 
4.24 ± 
0.02 
>100 >100 
4.21 ± 
1.38 
11.1 ± 
4.0 
C37 
5.97 ± 
0.42 
85.0 ± 
6.4 
4.12 ± 
0.52 
73.7 ± 
7.3 
7.74 ± 
0.54 
> 100 
4.77 ± 
1.04 
14.8 ± 
2.0 
P2-RANTES 
+ C37 (1:1) 
0.53 ± 
0.23 
7.15 ± 
0.17 
0.18 ± 
0.15 
5.67 ± 
0.12 
10.1 ± 
7.9 
>100 
1.67 ± 
0.07 
4.76 ± 
0.21 
CI 1.06 0.70 0.95 0.73 N.D. N.D. 0.41 0.42 
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FACS analysis  
 
In order to study the mechanism of this moderate synergy between P2-RANTES 
and gp41 binding peptides, we hypothesized that the internalization of CCR5 to remove it 
from the cell surface by P2-RANTES may play an important role.  As published by 
Hartley et al. (33), P2-RANTES not only tightly binds to CCR5 as other chemokines do, 
but also strongly internalizes the cell surface CCR5, while having negligible signaling 
effects on receptors CCR3 and CCR1 (33).  RANTES also induces CCR5 initialization 
but inefficient compare to the AOP-RANTES (124).  We used steady-state CCR5 down-
modulation FACS experiments to study the internalization of CCR5 on HeLa-TZM cells 
by treatment with individual or a combination of drugs in 30 min of incubation at 37 ºC.  
As shown in Figure III-4, free C37 did not induce CCR5 internalization as expected, wild 
type RANTES caused minimal CCR5 internalization with the highest concentration (100 
nM), but free P2-RANTES or P2-RANTES combined with C37 (1:1 ratio) showed 
significant internalization of CCR5 in a concentration dependent manner.  This 
significant difference between wild type RANTES and P2-RANTES may play a role in 
the moderate synergy observed by P2-RANTES:C37 compared to wild type 
RANTES:C37, which shows no synergy.  As a control, we also carried out a FACS 
analysis of CD4 levels on the surface of PBMC in the presence and absence of P2-
RANTES and C37.  Since neither P2-RANTES nor C37 has been shown to interact with 
or modulate CD4 levels at the cell surface, it was predicted that these molecules would 
not affect CD4 levels.  As expected, neither P2-RANTES nor C37 nor their 1:1 or 10:1 
combination had an effect on surface CD4 levels in PBMC (data not shown).  
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Figure III-4:  CCR5 internalization, as measured by FACS.   
The effect of free C37, P2-RANTES and the combination of wild type RANTES:C37 
(1:1 ratio) and P2-RANTES:C37 (1:1 ratio) on the cell surface CCR5 population of 
HeLa-TZM cells was measured.  Data are plotted as histograms of fluorescence 
intensity (cell surface CCR5), with the cell number normalized for each sample.  
The level of CCR5 expression is represented for cells treated with: 0 nM drug 
(black, shaded), 1 nM (brown), 10 nM (blue) and 100 nM (green). The cells stained 
with the secondary antibody but in the absence of CCR5 antibodies are shaded in 
light gray. Cell viability was determined by staining with propidium iodide (PI) at 
1µg/ml final concentration 1 minute prior to analysis.  Each histogram represents 
between 9000 and 9400 viable cells.  Viability of the cells varied from 95% to 97%. 
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Discussion 
 
 HIV-1 entry into cells requires cell surface protein CD4 and coreceptor CCR5 or 
CXCR4 (119,121,122,125-127).  CCR5 serves as the main coreceptor for transmitting 
HIV-1 infection (128), and  CCR5 density level (molecules/cell) on CD4 T cells have 
been shown to be the driving force of cell-cell fusion (63,129).  Reeves et al. (35,130) 
showed that “low” CCR5 density levels in cell lines lead to slower fusion kinetics and 
increased susceptibility to the C-peptide T-20.  In addition, CCR5 levels were shown to 
affect the sensitivity of primary cells to T-20 (34).  Rapamycin, which reduces CCR5 
density on cells, was recently shown to moderately synergize with T-20, giving a dose 
reduction in T-20 of about 33-fold (22,131).   
Synergy between drug therapies is an important strategy to allow effective disease 
control at low doses of drug (103,106-109,132,133).  Several combinations of anti-HIV 
compounds have been reported that involve fusion inhibitors, including CCR5 antibodies, 
CCR5 antagonists and fusion inhibitors (103,105,108,109).  Among the best of these, 
PRO 542 (a fusion of multiple CD4 subunits with immunoglobulin) and T-20 were 
shown to have strong synergy, with a combination index value of 0.34 at 50% inhibition 
in a cell-cell fusion assay (106).  Even better synergy was reported by Safarian et al. who 
observed a CI50 of 0.06 for the combination of anti-CCR5 antibody PA14 and small 
molecule SCH-C; however, these authors do not report a dose reduction (107).   
We report here a putative effective combination of anti-HIV agents, namely the 
combination of P2-RANTES and the gp41-binding peptides C37 and C34.  This 
combination shows potent anti-HIV activity mainly in fusion assays and in some cases 
against viral infection.  P2-RANTES and C37/C34 show synergy in fusion assays using 
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HeLa-P5L and HeLa-ADA cells.  In the same assays RANTES and C37/C34 only show 
additivity. 
One possible explanation for these results is that P2-RANTES internalizes CCR5 
receptors better than RANTES, which FACS analysis supports in TZM cells.  According 
to this analysis, RANTES causes minimal CCR5 receptor internalization at 100 nM.  On 
the other hand, P2-RANTES significantly internalizes the CCR5 receptor at the same 
concentration.   
Nevertheless, it is unclear whether or how these proteins will induce CCR5 
internalization in different cell types.  Mack et al showed that 100nM RANTES caused 
~20% CCR5 internalization in CHO/CCR5 cells, but at the same concentration, 
RANTES caused ~70% CCR5 internalization in PBMC (124).  This phenomenon may 
explain the observation that the combination of P2-RANTES and C37 acts synergistically 
in inhibiting HIV infection in PBMC cells but not in MAGI cells on the same viral strain 
Ba-L (Table III-3).  
In Figure III-4 it becomes obvious that CCR5 internalization is heavily dependent 
on the concentration of P2-RANTES.  At 1 nM concentration, P2-RANTES only slightly 
internalizes CCR5.  This may explain why in MAGI cells we observe synergy in the IC90 
but not in the IC50, since in IC90 higher concentration of P2-RANTES was used, so at this 
concentration P2-RANTES may be better able to internalize CCR5.  Very low 
concentrations of P2-RANTES may not cause significant CCR5 internalization and virus-
cell fusion kinetics remain the same (35,130). 
We also tested the hypothesis that different ratios of P2-RANTES : C37/C34 may 
affect the synergistic relationship of these two compounds in the fusion assay.  None of 
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the different ratios of P2-RANTES : C37/C34 tested gave better synergy than the 1:1 
ratio (Table III-2).  It is unclear why a 1:1 ratio is best, but it seems again that low 
amounts of P2-RANTES may not cause significant CCR5 internalization.  It also appears 
that low amounts of C37 in the case of P2-RANTES:C37 (9:1) does not help synergy.  
In all of the above experiments, it is inconclusive how general of a phenomenon 
the synergy we observed between P2-RANTES and C37/C34 in cell fusion assays is.  It 
is clear that the cell type, the amount of CCR5 receptors on the cell surface, CCR5 
receptor internalization and recycling are important parameters that affect the outcome of 
P2-RANTES and c-peptide combination.  Because the overall synergetic effect of the two 
compounds that we measured in the fusion assay was not that great (P2-RANTES:C37 
(1:1) gives CI: 0.52) (Table III-1), our focus shifted to other HIV inhibitors that were 
more promising (see Chapter II). 
On the next chapter, I am moving from the area of virology to the area of 
bioinformatics and I am working on finding unfavorable sequence motifs using 
phylogenetic and structural information. 
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CHAPTER IV
  
CONSERVATION OF
 
UNFAVORABLE SEQUENCE MOTIFS THAT
 
CONTRIBUTE TO THE CHEMOKINE QUATERNARY STATE* 
 
Introduction 
 
The second chapter of this dissertation uses CXCL8 to study the intriguing issue 
of the ability of proteins to dimerize. Although protein interactions can act both favorably 
and unfavorably, they are usually thought to be favorable and act in specific ways to help 
bring about a certain outcome in protein structure.  Interactions can also be unfavorable, 
but by their very nature, they are not often thought to actively contribute to protein 
structure.  In addition, discrete motifs producing unfavorable interactions have not been 
widely studied, because they are predominantly nonspecific and produce negative results 
that cannot be interpreted.  However, specific unfavorable interactions have been used in 
protein design to prevent certain outcomes from occurring (134,135) and have been 
characterized in the termination of β-sheet structures (136).  These unfavorable 
interactions should not be confused with the results from negative selection, where 
positive interactions are directly removed (137), or general negative design (138), where 
certain interactions are disfavored (139).  Although general negative design strategies 
produce unfavorable interactions, specific motifs are not used to achieve their goal. In 
this work, we want to identify evolutionarily conserved motifs that confer unfavorable 
                                                
 
*
 Reprinted with permission from “Conservation of unfavorable sequence motifs that contribute to the 
chemokine quaternary state.” from (143) Kagiampakis I, Jin H, Kim S, Vannucci M, LiWang PJ, Tsai J, 
2008. Biochemistry. 2008 Oct 7;47(40):10637-48 Copyright © 2008 American Chemical Society 
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interactions and characterize their role in determining protein quaternary structure. To 
accomplish this, we developed a predictive method combining structural with 
phylogenetic analysis that is validated using Bayesian variable selection (140).  This 
approach was used in an investigation of how unfavorable interactions contribute to the 
chemokine dimerization state. 
Chemokines are extracellular signaling proteins that play a general role in the 
innate and adaptive immune response, angiogenesis, cancer, and wound healing (32,141-
143).  In mammals, chemokines are separated into four main groups on the basis of the 
number of amino acids between the conserved cysteines (C) at the N-terminus of the 
protein (CXC, CC, CX3C, and C, where X is any amino acid).  The largest group of 
chemokines consists of the CXC chemokines (21 human members) and the CC 
chemokines (29 human members) (Cytokine Family Database, 
http://cytokine.medic.kumamoto-u.ac.jp/).  With the exception of some transmembrane 
domains containing chemokines, these proteins are generally small molecules (8 kDa). 
While the overall level of amino acid sequence conservation of the family is low, they all 
share the same tertiary fold of a single α-helix across a three-stranded antiparallel β-sheet 
(Figure IV-1) suggesting that they most likely originated from a common ancestor.  At 
the quaternary level, chemokines can form dimers, tetramers, or even heterodimers 
(144,145).  Possible roles of this oligomerization have been linked to chemokine function 
(146), such as suppression of specific surface-dependent neutrophil responses (147,148) 
and increasing in vitro antiproliferative effects (149).  For homodimers, the quaternary 
structures of chemokines from different groups dimerize in different ways.  As shown in 
Figure IV-1, CXCL8 chemokines interact across their β1 strands to form a globular 
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dimer, and in contrast, CCL4 dimerizes with its uncoiled N-terminus in a more extended 
conformation. While seemingly straightforward, attempts to disrupt the CXCL8 
homodimer and retain the chemokine fold have required a set of mutations 
(144,145,147,150,151) from simultaneous changes in both the β1 strand and α-helix to a 
chemical modification of L25 (Table IV-1).  In this work, we used a directed, 
computational approach to discover evolutionarily conserved motifs that produce a 
correctly folded CXCL8 monomer. 
Because all chemokines share a common tertiary structure yet the CXC and CC 
subfamilies generally interact with different quaternary forms (Figure IV-1), we 
hypothesized that there must be motifs in the CC subfamily (dimerizing between their N-
termini) that disfavor CXCL8 dimer formation across the β1 strand but still conserve the 
chemokine fold.  To discover these sequence elements, our approach to sequence analysis 
focused on increasing the magnitude of the signal of conserved differences and 
decreasing the noise from differences caused by random mutations.  Therefore, we 
limited our sequence analysis structurally to only the CXCL8 dimerization region (Figure 
IV-2) and evolutionarily to two CC clades (the one including CCL4 and another 
including CCL2; see Figure IV-3).  The results underwent rigorous statistical validation 
to separate true negative motifs from all the other noise produced in an alignment (140).  
On the basis of this work, we created three variants of CXCL8: two mutants that should 
induce a stable monomer and one control mutant that should not.  Surprisingly, one of the 
predicted monomeric mutations involves a very drastic two-residue deletion within the 
dimerization interface.  For the two evolutionarily conserved motifs from the CC family 
placed into a CXCL8 background, we experimentally prove they inhibit β1 strand 
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dimerization, while retaining the chemokine fold.  The control exhibited only a moderate 
decrease in the level of dimerization.  These results demonstrate that sequences 
conferring unfavorable interactions are evolutionarily conserved, and the implications of 
these findings related to chemokine quaternary structure are discussed. 
 
 
Figure IV-1:  Comparing the quaternary structure of the CXCL8 and CCL4 
homodimers.  
All images were created using PyMOL. (A) Showing PDB entry 3il8 (152), CXCL8 
dimerizes using the β1 strand and the α-helix. (B) Showing PDB entry 1hum (153), 
CCL4 dimerizes using the largely unstructured N-terminal region and the loops 
between strands β2 and β3. This interface forms eight interdomain hydrogen bonds: 
four from the small section of the antiparallel β-sheet formed by the β0 strands and 
four more backbone−backbone hydrogen bonds with the β3 strand. Apart from 
interactions with the β0 and β3 strands, CCL4’s homodimer interacts primarily 
through hydrophobic interactions between residues that do not form canonical 
secondary structure elements. (C) CXCL8’s β1 strand residues involved in the 
antiparallel β-sheet quaternary interaction are shown in space filling models. 
Overall, the CXCL8 interface forms eight hydrogen bonds and the molecular area 
of interaction is 361 Å2, where 303 Å2 comes from side chain interactions and only 
58 Å2 comes from backbone interactions. Specific details are illustrated in Figure 
IV-2. (D) Space filling models of the corresponding residues shown on CCL4 that 
are involved in CXCL8’s β1 strand antiparallel β-sheet quaternary interaction. 
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Table IV-1:  CXCL8 and its variants. 
a In section A are listed the wild-type CXCL8 amino acid composition and the 
number and secondary structure of residues involved in the dimer interface shown 
in Figure IV-7 A,C, and 16.  Secondary structure is given by sheet (E), helix (H), and 
coil (C) as defined by DSSP (154). The periods between residue numbers represent 
breaks in the sequence.  The statistical analysis is given in section B.  BVS stands for 
Bayesian variable selection. Amino acid substitutions shown in black and 
underlined represent strongly identified sites, whereas those shown in black are 
weakly identified sites (see Experimental Procedures).  Sites not predicted are 
shown in gray with the wild-type amino acid.  The deltas (∆) are deleted residues in 
sections B−D.  While analysis across all the residues was shown for completeness, 
this study focuses on only the analysis across the β1 strand (residues 24−28) and 
only those unique to the CC subfamily clade.  For instance, we did not include the 
L25Y substitution, since it is seen in analysis with both clades.  Section C lists 
CXCL8 variants used in this study.  Mutations are shown in black, while the 
unchanged native sequence is shown in gray.  Again, the complete wild-type 
sequence is shown along with the three variants used in this study: ∆RV, V27R, and 
R26A/V27A.  In addition, we show the dimerization constant Kd (micromolar) and 
indicate monomer/dimer state, where M refers to monomer, D to dimer, and wD to 
weak dimer.  Section D gives the same information for published mutations from 
previous experiments in the CXCL8 interface ordered by year the study was 
published.  Following the same conventions, we show the amino acids to which 
residues are mutated in black and the native unchanged sequence in gray. L′ 
represents an N-methylleucine. 
 
89 
 
 
Figure IV-2:  CXCL8 homodimer interaction interface.  
(A) Quaternary contact plot. (B) Residues across the β1 strand interface.  For panel 
A, contacts were calculated using Qcontacts (155) and are listed in Table IV-2.  
Because the dimer interface is symmetric across the diagonal, we can plot the 
hydrophobic carbon−carbon contacts as filled squares (  ) above the diagonal and 
the hydrogen bonds as filled triangles (▲) below the diagonal.  The plot clearly 
shows the three areas of interaction across the dimer interface.  The α-helices from 
each CXCL8 monomer form a loose hydrophobic network, and this interaction 
between helices is centered on the interaction between the two L66 residues.  The 
next part of the CXCL8 interface involves the C-terminal, α-helical residues 65−72 
interacting with residues 27−37 running from the β1 strand into and through the 
turn between the β1 and β2 strands.  In addition to the many hydrophobic contacts, 
two hydrogen bonds are formed (one from each monomer) between the side chain 
oxygen of T37 and the backbone carbonyl of A69.  The last area across the two β1 
strands of the CXCL8 homodimer contributes >50% of the interaction surface area 
as well as hydrogen bonds to the interface.  Each monomer’s edge β1 strand from 
residue 23 to 28 forms a regular antiparallel β-sheet interaction that unites a single 
six-stranded β-sheet with six backbone hydrogen bonds and a large, continuous area 
of interaction.  For the whole interface, residue R26 sits on the axis of symmetry 
(interacts with the same residue on the opposing monomer) and coincidentally 
buries the most surface area. This is clearly shown in panel B, where residues E24, 
R26, and I28 are shown in the antiparallel sheet between the two β1 strands. 
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Table IV-2:  Quaternary analysis of CXCL8.   
These quaternary interactions were calculated using the Qcontacts (155), where 
interaction type is defined.  In the table, the designations are H for hydrogen bond 
and V for hydrophobic van der Waals contact 
. 
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Figure IV-3:  Phylogenetic tree of the vertebrate CCL chemokine family.  
With the red color we underline the CCL2 clade and with the blue the CCL4 clade.  
The Neighbor Joining Tree was calculated using a Blosum 62 matrix from ClustalW 
program and the graphical representation of the tree was done using the Pfaat 
program. 
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Experimental Procedures 
 
CXCL8 dimer and monomer surface area calculation 
 
CXCL8’s molecular surface area across its dimer interface was calculated using a 
Voronoi polyhedron-based procedure (155).  The residue interactions are provided in 
Table IV-2.  We used all 30 NMR1 structures of the CXCL8 dimer in PDB entry 2IL8 
(156) for our calculations to allow for and sample the possible fluctuations across the 
dimer interface. Only contacts occurring in more than 15 of 30 structures were considered 
as an interaction and are shown in Figure IV-2.  Values reported in Table IV-2 are 
averages. 
Sequence alignment 
 
All the protein sequences of the vertebrate CC chemokines that were highly 
similar to CXCL8 were downloaded from the Cytokine Family cDNA Database 
(http://cytokine.medic.kumamoto-u.ac.jp/).  Sequences from signal peptides were not 
included.  Using the phylogenetic tree shown in Figure IV-3, a ClustalW (157,158) or 
DiAlign (159) (depending upon the circumstances) multiple-sequence alignment was 
created using all the sequences of CC chemokines for every single node and starting from 
the bottom of the tree.  The alignment in the initial node was found to be significant in 
cases where the multiple-sequence alignments in the area of CXCL8’s dimerization 
remained partially unchanged in the smaller subtrees.  Using this procedure, two major 
subtrees with constant differences in the area of CXCL8’s β1 strand were constructed and 
named clade CCL4 (29 sequences in the blue subtree, Figure IV-3) and clade CCL2 (16 
sequences in the red subtree, Figure IV-3).  The sequences in these two clades were used 
to create the logo figures.  To ensure the accuracy of the gap discovered at positions R26 
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and V27 of CXCL8 (Table IV-1), the alignment was repeated using DiAlign, which does 
not use gap penalties but the best diagonal without gaps in the alignment matrix (160).  
This alignment also predicted the two-residue deletion (data not shown).  While the 
phylogenetic tree in Figure IV-3 suggests that these two mutations diverged from a 
common ancestor, it could equally be the case that a monomeric ancestor existed.  This 
analysis considers only the differences between sequences and does not include bias 
about how they originated. 
Validation by Bayesian variable selection 
 
The method itself was discussed in more detail previously (140).  We compared 
sequences only within the area of interaction defined above based on a simple hydropathy 
profile (161).  To identify structural dissimilarities in protein alignments, we have applied 
the well-known variable selection method for classification with probit models proposed 
by Sha et al. (162).  Bayesian variable selection is done via a binary vector with p entries 
that identifies the different sets of variables.  The marginal posterior distribution of this 
binary vector is derived, and Markov chain Monte Carlo algorithms are used to sample 
from its posterior distribution.  The method allows the identification of sets of 
discriminating variables and the classification of future samples (via least-squares or 
Bayesian model averaging).  A site is identified as significant when there is a high 
posterior probability that the site is dissimilar (has had a mutation).  Conversely, those 
sites that are not identified are those that have a small probability of being dissimilar.  
Classification of strong and weak was determined on the basis of a comparison from two 
runs using different input parameters: strong sites were those identified by both runs and 
weak ones those identified by only one.  The sensitivity of the method to the input 
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parameters has been discussed previously (162).  Because we are working from only one 
CXCL8 sequence, we needed to cross-validate our results.  Once we identified the sites 
with a high posterior probability of being dissimilar, we tested how well we could 
discriminate between the groups (for example, CXCL8 from CCL2) on the basis of these 
sites.  Taking one CCL2 sequence out, we try to “predict” whether this sequence is more 
similar to CXCL8 or to the other CCL2.  If the answer should be the latter, it was 
considered a zero error. 
Construction and purification of mutants 
 
All the CXCL8 mutants were created in the pET-32a+ (Novagen) vector using 
Quikchange mutagenesis (Stratagene) and were confirmed via sequencing.  Protein 
purification for all mutants and the wild type (WT) used a standard chemokine refolding 
protocol as described previously (112). 
Size exclusion chromatography 
 
The purified protein was first dissolved into 20 mM sodium phosphate buffer (pH 
2.5) containing 150 mM NaCl, and then the pH of the solution was adjusted to 6.7 with 4 
M NaOH.  The solution was centrifuged at 12000 rpm for 20 min to remove any possible 
precipitation.  The dissolved refolded protein (0.5 mL) was loaded onto a Superdex G75 
(HR 10/30) gel filtration column (GE Healthcare) equilibrated with 20 mM sodium 
phosphate buffer (pH 6.7) containing 150 mM NaCl.  The protein was eluted with this 
buffer and run using the Pharmacia Akta system.  The gel filtration column was 
calibrated with several standard marker proteins (Bio-Rad) in the same running buffer, 
and the molecular masses of chemokine variants were estimated using the calibrated 
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standard curve.  All sample elutions were performed at a rate of 0.4 mL/min; 1 mL 
fractions were collected, and the protein content was analyzed by 12% SDS−PAGE. 
Analytical ultracentrifugation (AUC) 
 
Sedimentation equilibrium data were collected on a Beckmann XL-A analytical 
ultracentrifuge using the An-60 Ti rotor at 25 °C.  The following sets of speeds were used 
for each mutant: 26500 and 36500 rpm for R26A/V26A, 26500, 37500, and 48000 rpm 
for ∆RV, and 25000, 27500, 30000, 32000, 34000, 36000, and 38000 rpm for V27R.  
The absorbance for all three mutants was measured at 280 nm to determine the 
concentration of the protein during the sedimentation equilibrium.  For V27R, the 
absorbance was measured at two additional wavelengths (235 and 245 nm).  For each 
run, protein was dissolved in sodium phosphate buffer with 150 mM NaCl at pH 6.2.  
Initial protein concentrations were 110 µM for R26A/V26A and 25, 50, and 111 µM for 
∆RV.  For V27R, eight different concentrations between 50 and 500 µM were used.  The 
data were processed using the Ultra Scan Data analysis software 
(http://www.ultrascan.uthscsa.edu/).  The calculated molecular masses and dissociation 
constants as well as their respective standard deviations were calculated on the basis of a 
Monte Carlo simulation of the initial global fitting over all the data collected. 
NMR spectroscopy 
 
NMR samples of 1 mM protein for all the variants were prepared in 150 mM 
NaCl, 20 mM sodium phosphate (pH 6.7), 0.01% NaN3, 0.1 mM DSS, and a 95% 
H2O/5% D2O solvent mixture.  The spectra were collected on a Varian Inova 600 MHz 
spectrometer at 25 °C. 1H, 13C, and 15N chemical shifts were referenced to internal DSS 
(163).  Sequence specific backbone assignments of 13Cα, 13Cβ, and 15N were obtained 
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from CBCA(CO)NH and CBCANH experiments (164).  For structure comparison, 
1H−15N HSQC spectra were acquired with 512* points in the 1H (direct) dimension and 
64* points in the 15N (indirect) dimension, where n* represents n complex points.  The 
spectral width for 1H was 8000 Hz and for 15N was 1700.68 Hz.  Total acquisition times 
were 64 ms for the 1H and 37.6 ms for the 15N dimension.  The relaxation experiments 
were performed according to the following.  The spin-lattice (T1) and spin-spin (T2) 
values were determined for 1mM 15N labeled CXCL8_∆RV, from 15N-1H-HSQC spectra 
collected using pulse sequences described above.  Intensities of cross-peaks were 
obtained from peak-picking routines provided in the software PIPP package.  Data from 
each amino acid residue was extracted in a straightforward fashion by measuring the 
intensities of cross-peaks in 15N-1H-HSQC spectra as a function of a relaxation delay.  
The 15N T1 data was collected with 15N delays of 0.02, 0.1, 0.12, 0.18, 0.25, 0.36, 0.52, 
0.76, 1.00, and 1.25 s. T2 data was collected using 15N delays of 32, 48, 64, 80, 96, 128, 
144, 160, 192, and 240 ms. The T1, T2 data sets were processed using software nmrPipe 
(165).  Data was excluded from the correlation time calculation if either T1 or T2 differed 
from the average value by >1 SD. 
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Results 
 
Structural analysis of the dimer interfaces 
 
We go into only as much detail comparing the CXCL8 and CCL4 interfaces as 
necessary to provide background to our analysis, since this comparison has been made 
previously (153) and in greater evolutionary and molecular detail (166).  For the sake of 
consistency, we follow the same nomenclature.  The monomers are 18% identical with 
each other in sequence, yet both exhibit the same fold (Cα rmsd between CXCL8 and 
CCL4 of 1.6 Å) as shown in Figure IV-1: a single α-helix over a β-sheet arranged in a 
Greek key motif (all the β-strands are antiparallel to each other and are numbered from 
the N-terminus β0, β1, β2, and β3).  Even though they are so similar, each possesses 
certain unique features.  CCL4 exhibits a small, extra section of β-sheet structure near the 
N-terminus, while CXCL8’s α-helix is one turn longer at its C-terminal end.  As Figure 
IV-1 clearly shows, CCL4 and CXCL8 dimerize quite differently.  The CCL4 homodimer 
is elongated and interacts primarily through N-terminal β0 strand residues 2−16 with two 
areas on the opposing monomer: the same residues as well as residues 46−51 of the β3 
strand (Figure IV-1B).  In contrast, the CXCL8 dimer is more globular, and the 
dimerization interface appears more uniform (Figure IV-1A and highlighted in Figure 
IV-1C). From an analysis of quaternary interactions (155), the CXCL8 dimer interface 
combines interactions across three areas (Figure IV-3 and Table IV-1).  Of the three, the 
interaction area that has drawn the most focus is the β1 strand, since it contributes the 
most surface area and hydrogen bonds to the homodimer interface (166).  In contrast, the 
β1 strand does not contribute at all to the CCL4 homodimer, and as emphasized in Figure 
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IV-1D, CCL4’s β1 strands do not contact each other in its dimer state.  For these reasons, 
we have focused our sequence analysis on the β1 strand to identify the inhibitory 
sequence elements in the CC family of chemokines that disfavor the CXC 
homodimerization state. 
Identifying conserved sequences conferring negative interactions 
 
Structurally limiting our comparison to only a fragment of the CXCL8 sequence 
and evolutionarily to only CC chemokine subfamilies is unlike previous work that has 
tried to mutate the conserved residues found from an alignment over the entire 
chemokine sequence (144,145,147,150,151,166).  As shown in Figure IV-4A, the breadth 
of such an alignment diminishes the conservation signal of all residues and the global 
alignment misaligns this region by a single-residue shift toward the C-terminus.  As a 
result, many attempts to create a stable monomer have been performed, and each has used 
multiple point mutations (Table IV-1).  Instead, we performed a more focused and 
statistically rigorous analysis that considered only those residues involved in the β1 
strand of the CXCL8 dimer interface and also limited the comparison of the CXCL8 
sequence to only an evolutionarily related subset or clade of the CC chemokine family.  
Although the approach is more thoroughly discussed in Experimental Procedures, we 
briefly summarize the steps and reasoning behind it.  The clade analysis is based on the 
hypothesis that proteins with the same tertiary fold but different quaternary structure must 
have taken separate evolutionary paths from a common ancestral sequence and may have 
selected different mechanisms to achieve the same result.  The choice of sequences to 
include in our clade analysis was defined by the branches in a phylogenetic tree of the CC 
chemokines (Figure IV-3).  As the last step, the significance of our results was verified 
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using a rigorous statistical method based on Bayesian variable selection (140) to filter out 
any insignificant results due to the low complexity of the sequence space. 
 
 
 
Figure IV-4: Logo plots of the β1 strand region.   
Three multiple sequence alignments are represented using Weblogo (167).  The 
overall height of the stack indicates the conservation at that position in the multiple-
sequence alignment, and the height of the individual single-letter codes within the 
stack indicates the relative frequency of the corresponding amino acid at that 
position.  The x-axis values refer to the residue position of the mature human 
CXCL8.  Color coding for the class of amino acids: green and purple for polar, blue 
for basic, red for acidic, and black for hydrophobic.  (A) Problems of a global 
multiple-sequence alignment over the entire CC chemokine family with the CXCL8 
sequence. One is the reduction of the magnitude of the signal (see the smaller letters 
of the Arg residues at positions 27 and 28), and another is the apparent +1 residue 
shift in the middle of the alignment as compared to the two following alignments 
(see the shift in the Tyr residue at position 26 and the Arg residues at positions 27 
and 28). (B) Results of the multiple-sequence alignment comparing the CXCL8 
sequence with the sequences from the clade surrounding CCL4.  The deletion in the 
center at positions 26 and 27 is quite evident.  (C) Results of the multiple-sequence 
alignment comparing the CXCL8 sequence with the sequences from the clade 
surrounding CCL2.  Again, the conservation of the Arg at positions 26 and 27 is 
very apparent. 
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On the basis of this procedure, we were able to identify a set of mutations that 
help us understand how the CC chemokine families negatively design against CXCL8 
dimerization (summarized in Table IV-1).  Because CCL4 possesses the same fold as 
CXCL8 yet dimerizes differently [as explained above (166)], our first comparison uses 
the clade surrounding CCL4.  The sequence alignment shown in Figure IV-4B clearly 
indicates a two-residue deletion of R26 and V27 in the β1 strand.  While a number of 
other residues exhibit strong conservation, only the two-residue deletion and the L25Y 
mutation exhibited statistical significance (Table IV-1).  To further test this approach, we 
also made the same limited sequence comparison of CXCL8 with the CCL2 sequence 
clade.  Sharing the same chemokine fold, CCL2 dimerizes in a fashion similar to that of 
CCL4 (168) but also shares a low level of sequence identity with CXCL8.  As 
corroborated by our statistical analysis, Figure IV-4C highlights the existence of the two 
Arg residues in the center of the β1 strand created by a V27R mutation.  Because we 
wanted to understand the sequence elements conferring negative interactions specific to 
each evolutionary branch, the L24Y mutation was disregarded since it was conserved 
across both the CCL4 and CCL2 clades.  Therefore, our analysis produced two sets of 
negative interaction elements that break up a CXCL8 dimer yet retain the chemokine 
fold: a deletion of residues 26 and 27 (∆RV) and a mutant creating a charge repulsion 
(V27R).  As a control to test whether removal of the side chains or the rearrangement 
caused by the deletion is more important, the R26A/V27A double mutation was also 
introduced. 
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Monomeric state of the mutants 
 
The two variants of CXCL8 (∆RV and V27R) along with R26A/V27A and the 
WT control were constructed and purified as described in Experimental Procedures.  It is 
predicted that making these mutations in CXCL8 will abrogate the dimer.  For the sake of 
clarity, we will further refer to these mutations using their abbreviated names indicated in 
the previous sentence and noted in Table IV-1.  Size exclusion chromatography (SEC) 
and analytical ultracentrifugation (AUC) were used to investigate the quaternary state.  In 
the SEC analysis, we compared the elution profiles of WT CXCL8 to those of the ∆RV 
and R26A/V27A mutants of CXCL8 (Figure IV-5).  The major peak in the ∆RV profile 
eluted at a volume later than that of the WT that is quite similar to known CXCL8 
monomeric mutants (112).  In contrast, the R26A/V27A control variant of CXCL8 elutes 
only slightly later than wild-type CXCL8, but significantly before known monomeric 
variants.  This similarity in elution profile to the WT suggests that the R26A/V27A 
variant forms a dimer in solution.  To further verify the dimerization status of these 
variants, the more rigorous AUC experiment was carried out. A single run for each 
mutant is shown in Figure IV-6; however, for the sake of accuracy, the oligomerization 
state was modeled from an extensive set of AUC experiments (see Experimental 
Procedures) performed for each variant at different speeds, wavelengths, and 
concentrations (Data not shown).  The result of the AUC analysis is that both the ∆RV 
and V27R mutants fit a monomeric model with predicted molecular masses of 8.25 ± 
0.52 and 8.74 ± 0.21 kDa, respectively.  These values are close to the theoretical 
monomer molecular masses of these mutants.  These fits of ∆RV and V27R mutants were 
run at concentrations of up to 111 and 500 µM (see Experimental Procedures), 
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respectively, which is far greater than the WT value of 0.194 µM (112) run under the 
same conditions.  In comparison to other values of the WT, the Kd values of CXCL8 run 
under slightly different conditions ranging from 4 to 10 µM (150,169-171), these mutants 
are monomeric.  Therefore, they show that the mutations strongly inhibit dimerization 
across the β1 strand.  The R26A/V27A control fits best to a monomer−dimer equilibrium 
model with an estimated molecular mass of the monomer of 8.8 ± 0.6 kDa and a Kd of 
18.2 ± 3.1 µM, which is a weaker dimer than WT CXCL8 [Kd = 0.1 µM (112)].  
Comparison to other values of WT CXCL8 Kd noted above substantiates that 
R26A/V27A still dimerizes in a manner comparable to that of WT CXCL8.  These results 
show that the mutation disrupts but does not abolish dimerization. These SEC and AUC 
results clearly demonstrate that the two types of evolutionarily conserved sequence 
motifs confer negative interactions to inhibit CXCL8 dimerization across the β1 strand. 
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Figure IV-5:  Size exclusion chromatography.  
SEC is shown for WT CXCL8, the ∆RV variant, and the R26A/V27A mutant. The 
black line shows the expected earlier position for the dimer, and the gray line 
represents the expected later position for the monomer. Elution volumes of the peak 
are shown on the x-axis. 
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Figure IV-6:  Individual analytical ultracentrifugation runs.   
Single AUC residuals (top) and fits (bottom) are shown for (A) ∆RV, (B) the V27R 
variant, and (C) the R26A/V27A mutant.  Speed and temperature are shown on 
each plot.  The wavelength is 280 nm for ∆RV, 281 nm for V27R, and 280 nm for 
R26A/V27A.  As explained in Experimental Procedures, although a single run is 
shown here, the oligomerization data were fit for each variant over several runs.  
Both the ∆RV and V27R mutants fit a monomeric model with predicted molecular 
masses of 8.25 ± 0.52 and 8.74 ± 0.21 kDa, respectively.  These values are close to the 
theoretical monomer molecular mass of these mutants.  The R26A/V27A control fits 
best to a monomer-dimer equilibrium model with an estimated molecular mass of 
the monomer of 8.8 ± 0.6 kDa and a Kd of 18.2 ± 3.1 µM, which is a weaker dimer 
than the WT (Kd ∼ 0.1 µM).  The randomness of residuals shown above each plot 
indicates a good fit.  
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NMR evidence indicating chemokine tertiary structure 
 
Because the quaternary state is sensitive to the tertiary state, we used NMR to 
determine whether the CXCL8 mutants formed a chemokine fold.  First, HSQC 15N−1H 
correlation spectra were compared. Figure IV-7 shows an overlay of the spectra of ∆RV, 
V27R, and WT CXCL8.  The differences between these monomeric variants and WT 
CXCL8 are most likely due to the loss of intermolecular contacts across the dimer 
interface.  We will first discuss the comparison of the HSQC spectra between the V27R 
mutant and WT, since it is only a single side chain mutation.  We are confident that at 
NMR concentrations of 1 mM (see Experimental Procedures), the V27R mutant is a 
monomer since the AUC data were recorded at 0.5 mM, close to the NMR concentration. 
In Figure IV-7, this monomeric V27R mutant exhibits good peak dispersion and displays 
a spectrum similar to those of other known CXCL8 monomers (112), so we conclude that 
the V27R mutant exhibits a chemokine fold. 
Because AUC for the ∆RV mutant was maximally run at 1/10 of the NMR 
concentration, we ran a 15N relaxation experiment to verify that this mutant was a 
monomer.  The ratio of 15N relaxation parameters T1 and T2 can be used to estimate the 
size of a protein.  For example, the wild-type CXCL8 dimer has been shown to have a 
T1/T2 ratio of 8.59 (172), and that of the CCL4 dimer is 8.3 (173).  In contrast, 
monomeric variants of CCL4 have measured T1/T2 ratios of 3.9 and 4.0 (174).  For this 
work, the CXCL8 mutant ∆RV was shown to have a T1/T2 ratio of 3.6, fully consistent 
with a monomeric chemokine.  In Figure IV-7, the well-defined dispersion in the 15N−1H 
correlation spectra is also representative of a folded protein.  Unlike the simple point 
mutation in V27R, the deletion of two residues in the case of the ∆RV mutant causes an 
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expected but significant change in the HSQC spectrum when compared to that of the WT.  
The deletion leads to loss of interactions across the protein−protein interface, and R26 
and V27 also make several intramonomer contacts in the wild-type protein. When an 
analysis of tertiary contacts was performed (175), R26 and V27 make internal contacts 
with I28, T37, E38, I39, I40, V41, and K42 (data not shown).  An assignment of 15N, 
1HN, 13Cα, and 13Cβ resonances was carried out and confirmed that the residues 
contacting R26 and V27 in WT CXCL8 change environment in the ∆RV mutant (Figure 
IV-8).  Although suggestive, the HSQC spectrum of the ∆RV variant does not provide 
conclusive evidence that this mutant retains the chemokine fold.  Therefore, we turned to 
an NMR-based analysis of secondary structure (176) and oxidative state of cysteines 
(177) to prove that the ∆RV mutant folds into the chemokine structure shown in Figure 
IV-7.  For secondary structure, we measured the 13Cα and 13Cβ deviation from random 
coil values (Figure IV-9), which has been established as a strong predictor of secondary 
structure (178,179).  While the β3 strand is approximately the same length in ∆RV as in 
the WT, the β1 and β2 strands appear to be shorter.  This potential fraying of the β1 
strand would contribute to inhibition of dimer formation.  In addition, the deviations in 
Figure IV-9 show that the helix in ∆RV is not structured toward the C-terminus.  Our 
T1/T2 ratios corroborate this result since they cannot be calculated past residue 65 in the 
15N relaxation experiment (data not shown).  The unstructured C-terminal residues are 
consistent with the loss of intersubunit contacts made by the helix as previously 
suggested (144) and explicitly described in a CXCL8 monomer (180).  However, despite 
these small variations, the two proteins overall appear to exhibit very similar secondary 
structures.  Analysis of the chemical shift assignments with TALOS (181) predicts and ψ 
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backbone torsion angles that corroborate our secondary structure analysis (data not 
shown).  Furthermore, the 13C NMR chemical shifts can distinguish between reduced, 
free cysteine and oxidized, disulfide-bonded cysteine (182).  Since the chemical shift 
assignments for the backbone atoms of WT and ∆RV have been obtained using a series 
of three-dimensional experiments, we can easily compare the participation of cysteines in 
disulfide bonds between the two variants.  As shown in Table IV-3, all of the 13Cβ 
chemical shift values for the four cysteines in ∆RV are similar to those of WT CXCL8 in 
that they are greater than the cutoff value of 32 ppm for the reduced cysteine (182), 
which indicates that all cysteines in the ∆RV mutant are in the oxidized disulfide form, 
like the wild-type protein.  In addition, the ∆RV’s cysteine 13Cβ and 13Cα chemical shift 
values deviate only slightly from the WT CXCL8 values.  Not only do these results show 
that the ∆RV mutant’s cysteines are disulfide-bonded, but they also indicate that the ∆RV 
disulfides inhabit an environment similar to that of the wild-type protein.  Therefore, 
∆RV very likely shares the same disulfide pattern as WT CXCL8.  Previous studies on 
the formation of these disulfide bonds have shown that they are integral to chemokine 
structure (183,184).  In much the same spirit that Anfinsen’s experiments used disulfide 
bonding patterns to prove correct refolding (185), the fact that ∆RV makes the same two 
disulfide bonds as WT CXCL8 (from β0 to β3 strands and from β0 to β2 strands) 
indicates that the β-sheet structure is like the WT.  This evidence of correct chemokine β-
sheet structure in conjunction with good dispersion in the 15N−1H correlation spectra and 
correct secondary structure formation strongly argues that, like the V27R mutant, the 
drastic ∆RV mutant retains a chemokine fold. 
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Figure IV-7:  HSQC spectra.  
Comparison of 15N-1H correlation spectra of wild-type CXCL8 to those of ∆RV and 
V27R.  As labeled, data for wild-type CXCL8 are colored black. For contrast, peaks 
for ∆RV and V27R are colored red and green, respectively. Both of the mutant 
proteins display good dispersion of peaks, which implies that they are well-folded. 
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Figure IV-8:  Chemical shift differences.   
The 15N- and 1HN-weighted average chemical shift differences between WT CXCL8 
and ∆RV are shown. The dashed black line represents the average chemical shift 
differences and the dashed gray line the standard deviation from the average. The 
weighted chemical shift differences (186) were calculated using the equation ∆δobs = 
{[(∆δHN)
2 + (∆δN/5)
2]/2}1/2.  In this analysis of peak movement, the assignment of 15N 
and 1HN resonances showed that many residues’ resonances in the β1 strand and 
the C-terminal portion of the R-helix change in the ∆RV mutant.  All these peaks 
move in comparison to those of the WT, except I39.  As discussed above, these 
expected changes in peak position indicate that the chemical environment around 
these amino acids has changed due to a lack of interface contacts and the two-
residue deletion.  In addition, the peaks corresponding to H33, C34, A35, and N36 
have shifted in ∆RV, so the turn between the β1 and β2 strands has been affected, 
possibly because of the changes in the registry of the amino acid at the turn. The 
peaks corresponding to L51 and D52, in the turn between the β1 strand and α-helix, 
have also moved.  Lastly, the peaks from L66, A69, E70, and N71, which belong to 
the top part of the α-helix, all have shifted. 
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Figure IV-9:  Chemical shift index values of 13Cα and 13Cβ deviations from random 
coil chemical shift values relative to DSS (2,2-dimethyl-2-silapentane-5-sulfonate 
sodium salt) (163).   
Data for WT CXCL8 are shown on top and those for the ∆RV variant on the 
bottom.  The vertical scale for the index is either -1, 0, or 1.  For each, the sequence 
is shown with the residue number underneath marked by tens.  Also, the secondary 
structures of sheets are helices and are noted, and dashed lines are provided for 
reference.  For better comparison, the ∆RV sequence is shifted over by two residues 
at the start.  Note for the ∆RV variant, the β1 strand is shorter and α-helix is four 
residues shorter than that of the wild type, as found for monomeric CXCL8 
(144,180). 
 
 
Table IV-3: Cysteine 13C chemical shifts. 
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Discussion 
 
In this investigation of differential chemokine quaternary structure, we applied a 
hybrid sequence analysis to identify conserved motifs within one chemokine protein 
interface and have experimentally shown that these motifs inhibit dimerization across the 
β1 strand.  In an effort to maximize the signal over noise, the sequence analysis 
considered structure (localization of comparison to a particular portion involving the 
CXCL8 dimer interface) and phylogeny (limiting the comparison to clades consisting of 
proteins closely related in evolution).  In comparing CXCL8’s sequence with the CCL4 
and CCL2 sequence clades, this analysis reveals that these two chemokine families 
conserved different motifs over their β1 strands (Figure IV-4).  For the CCL4 sequence 
clade, a surprising two-residue deletion is found in the middle of the β1 strand, while for 
the CCL2 sequence clade, a simple V27R point mutation is found.  As shown in Figure 
IV-4, limiting the sequence analysis is important.  Crystallographic evidence shows that 
certain CC chemokine families can dimerize like CXCL8 (187,188).  Including these 
sequences in our analysis would certainly cause ambiguity in the results, and as shown in 
Figure IV-4A, mutations suggested by a straightforward sequence alignment would not 
have found these sequence elements.  In addition, because the double deletion was 
located in the middle of a strand, a structural alignment would have certainly assigned the 
missing residues to either side of the strand in loop regions and missed the importance of 
the deletions’ position. 
Placing the ∆RV and V27R negative interaction motifs in the CXCL8 
background, we experimentally confirmed that these sequences affect CXCL8’s ability to 
dimerize across the β1 strand without changing the chemokine fold.  AUC and SEC 
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experiments indicate that the two CXCL8 variants form monomers and no longer 
dimerize (Figures 19 and 20, respectively).  NMR HSQC analysis shows good peak 
dispersion for both of the CXCL8 variants (Figure IV-7), where the V27R variant 
displays a pattern similar to that of folded monomers found in previous work (112).  
Because the ∆RV mutation is more drastic and its HSQC spectrum is so different, it 
could be argued that the ∆RV mutation causes some rearrangement in chemokine 
structure in either the β-sheet, β1 strand, or helix.  The NMR evidence showing the 
correct disulfide pattern (Table IV-3) verifies that the ∆RV variant forms a chemokine β-
sheet, at least among the β0, β2, and β3 strands, while the ∆RV mutant’s good dispersion 
in the 15N−1H correlation spectra results from a folded structure (Figure IV-8).  In Figure 
IV-9, the 13Cα and 13Cβ deviation from random coil analysis (176) indicates that the β1 
strand is formed and shows C-terminal fraying of the α-helix, which is indicative of a 
folded monomer in solution (180).  In comparison with previous work on creating 
CXCL8 monomers (144,145,147,150,166,169), these results demonstrate that our hybrid 
sequence analysis provides a straightforward and successful approach to identifying 
sequence motifs that inhibit dimer formation. Overall, our results show that the two 
conserved sequence motifs introduce unfavorable interactions into the CXCL8 interface 
and inhibit CXCL8 homodimer formation. 
The ∆RV and V27R motifs both disrupt CXCL8-type dimerization by more than 
just affecting the β1 strand interface.  Ostensibly, ∆RV is a gross modification in the 
middle of a β-strand, yet it retains a chemokine fold.  Because the R26A/V27A variant 
only weakens dimer formation by a ∆∆G of 12.9 kJ/mol, the ∆RV’s effects include the 
removal of the side chain interactions across the β1 strand and the double deletion alters 
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interactions of the downstream turn and α-helix (Figure IV-2 and Figure IV-4).  Both of 
these are involved in the dimer interface.  As the double deletion derives from the CCL4 
clade, this supposition is corroborated by the shortened β1 strand and downstream loop 
shown by CCL4.  Figure IV-8 provides a clearer, better explanation.  The β1 strand is 
shorter and the α-helix frayed toward the C-terminus in comparison to those of WT 
CXCL8, although the frayed α-helix is characteristic of a chemokine monomer (180). 
Such structural changes do not favor dimer formation.  By contrast, as a modest, single-
point mutation, the V27R substitution introduces a long positively capped side chain into 
the center of the CXCL8 interface that most likely creates an electrostatic repulsion with 
the adjoining R26 residue and a steric obstruction to the correct placement of the α-
helices during dimer formation.  A similar negative interaction has been found in a 
survey of protein β-sheet structures (136) and was used to inhibit dimerization in protein 
design (135).  While this mutation has been shown in conjunction with the L25Y 
mutation to cause a chemokine monomer (147), our work is the first reported, single-
natural amino acid substitution shown to disrupt the CXCL8 homodimer and retain the 
chemokine fold, where the other single-amino acid substitution was a non-natural l-
methylleucine at residue 25 (145) (Table IV-1).  These results for both the ∆RV and 
V27R negative interaction elements agree with previous work showing that mutations in 
both the β1 strand and α-helix are necessary to disrupt the CXCL8 dimer (144). 
The finding of conserved sequence motifs that disfavor a certain type of 
homodimerization has several implications.  First, these results suggest that at least one 
role of these motifs in the CCL4 and CCL2 sequence clades is to inhibit the more regular 
protein−protein interaction involving the β1 strand.  As displayed in Figure IV-4, these 
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motifs are strongly conserved. ∆RV is found in all 29 sequences in the CCL4 clade (blue 
subtree of Figure IV-3), while V27R is found in the majority of the 16 sequences in the 
CCL2 clade (red subtree of Figure IV-3).  For the other instances in the CCL2 clade, the 
residue is another positively charged lysine residue.  This conservation strongly suggests 
that there is some evolutionary pressure to retain these motifs.  One such pressure could 
be to favor N-terminal homodimerization.  Since crystallographic structures have shown 
that it is possible to see chemokine tetramers with both types of interfaces (189,190), we 
can think of the various homodimerization states being in equilibrium.  By disfavoring 
the β1 strand interface, the ∆RV and V27R sequence motifs indirectly favor 
homodimerization at the N-terminal interface.  Because the exact function of 
homodimerization with chemokines is still being debated (38,146,150,174,191-197), we 
cannot say for certain that the primary role of these motifs is to indirectly favor CC-type 
homodimerization.  However, with new evidence of chemokine heterodimerization (198), 
the inhibitory motifs could take on new significance by hindering cross reactivity with 
other chemokines in a CXC-like dimer.  Because of the striking evolutionary persistence 
and the clear experimental findings, our results do support the conclusion that the ∆RV 
and V27R sequence elements are examples of conserved motifs conferring unfavorable 
interactions against CXC-type dimerization. 
After the completion of this project, lab interest moved from chemokine 
dimerization studies to development of anti-HIV compounds since one of the most 
promising property of some chemokines, like for example RANTES, is to block HIV 
fusion to the target cell as it descript in details in Chapter I.  
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CHAPTER V  
SUMMARY, CONCLUSIONS AND FUTURE WORK 
 
Chapter II focuses on improving the properties of Griffithsin, a lectin that binds 
viral envelope glycoprotein gp120.  The hypothesis is that a covalently linked Griffithsin 
and C37 (Griff37) would allow both of these compounds to bind at the same viral spike.  
This simultaneous binding could be beneficial for the anti-HIV activity of Griffithsin.  As 
proof of concept, I used CD4M33, a peptide that also binds to gp120 at an area similar to 
Griffithsin, covalently linked to C37 (C37CD4M33C1F23).  Indeed, Griff37 showed better 
viral inhibition than Griffithsin alone both in fusion assays and viral assays in MAGI and 
PBMCs cells in R5 and X4 viral strains.  In the case of C37CD4M33C1F23, the lack of 
proper controls (CD4M33C1F23) made it difficult to appreciate the success of this chimeric 
protein. 
We consider Griff37 a good candidate for improvement, but before we do that, it 
is crucial to understand the mechanism of action of this chimeric protein.  Some of the 
experiments proposed here are currently under way.  The models proposed in Chapter III 
(Figure II-4) suggest that linker length is crucial in simultaneous binding of Griffithsin 
and C37.  Shorter linker length is expected to reduce the anti-HIV potency of Griff37.  If 
Griff37 with a shorter linker length has the same or higher anti-HIV activity, then the 
most probable model of action is shown in Figure II-4A, where Griffithsin and C37 do 
not bind simultaneously, but rather with one or the other.  In order to test the role of C37 
in Griff37, mutations will be introduced to C37 that cause a reduction in the binding 
affinity of C37 with viral protein gp41 (199).  The drawback of this experiment is that a 
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linked C37 may act differently from a free C37 and significantly affect the kon of C37, 
and the overall reduction of anti-HIV activity of Griff37 may be minimal. 
Before Griff37 experiments progress, it is crucial to verify that the improvement 
in potency that we observed compared to Griffithsin is general enough to make Griff37 a 
good candidate for practical application.  Griff37 needs to be tested in many more R5, R4 
and dual tropic HIV strains from subtype B and C.  Attention needs to be given to strains 
that show C37 resistance and Griffithsin resistance (some subtype C strains shows 
resistance to griffithsin (200)) since we expect the chimeric protein to show significant 
improvement in these viral strains (200).  It is also desirable to test the potency of Griff37 
in dendritic cells since, as I described in Chapter I, these are the cells that the virus 
encounters first as it travels deeper in the epithelium. Finally, if we receive satisfactory 
results from the experiments above, Griff37 should be tested in HIV-1 cervical explant 
assays and microbicide toxicity assays (67).  
In Chapter III, I test the hypothesis that there is a synergistic effect in HIV 
inhibition between P2-RANTES, a modified version of the chemokine RANTES, and C-
peptides C34 and C37.  These peptides block the formation of the six-helix bundle of 
gp41 (see Chapter I).  Although I observed synergy in a fusion assay between P2- 
RANTES and C37/C34, these effects seemed to be minimal when the compounds were 
tested in a viral assay in MAGI cells.  When the compounds where tested in PBMCs in 
viral assays, we observed synergy.  From these results, it was clear that the synergetic 
effect between P2-RANTES and C37/C34 was heavily dependent on the cell type, the 
amount of CCR5 receptor on the surface of the cell, and on the capability of the cells to 
internalize and recycle the CCR5 receptor.  Because of the lack of generality, and taking 
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into account the complexity of the virus-human interaction described in Chapter I, it is 
expected that the practical applications of the synergetic effects of these drug 
combinations will be limited.  Resources would be better spent on more attractive HIV 
fusion inhibitors. 
Chapter IV moves from the field of virology to bioinformatics.  In this chapter, I 
used a chemokine family to test the hypothesis that unfavorable sequence motifs can be 
evolutionarily conserved and can be detected using structural alignment combined with 
phylogeny. This chemokine family exhibited the same tertiary fold, but members of 
certain subfamilies, including CXCL8, formed a homodimer across the β1 strand, while 
members of other subfamilies, including CCL4 and CCL2, formed a homodimer on the 
opposite side of the chemokine fold.  These results suggest that, at least in this protein 
family, we detected conserved unfavorable sequence motifs.  The usefulness of this 
method can be summarized as a way to reduce the “noise” in structural alignment that is 
accumulated through random mutations in a protein sequence.  This is critical when we 
are searching for unfavorable sequence motifs that do not need to be evolutionarily 
highly conserved.  
Further tests are needed in different protein families with similar properties to 
verify the generality of this phenomenon.  The possibility of developing a user friendly 
structural alignment program that would take into account phylogeny information and 
would allow the user to determine the area of interest would be a breakthrough in 
detecting unfavorable sequence motifs and allow better understanding of the evolution of 
protein families. 
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NOMENCLATURE 
 
AIDS  Acquired Immune Deficiency Syndrome 
AOP  Aminooxypentane 
AUC   Analytical Ultracentrifugation 
BSA   Bovine Serum Albumin 
BME   β-Mercaptoethanol 
CCR   CC Chemokine Receptor 
CXCR  CXC Chemokine Receptor 
CHO   Chinese Hamster Ovary 
CRPG  Chlorphenol Red-β-D-Galactopyranoside 
EDTA  EthyleneDiamineTetraacetic Acid 
NOE   Nuclear Overhauser Effect 
PSC   [L-ThiaPro2, L-α-cyclohexyl-Gly3]-NNY 
Da   Dalton 
DSS   4, 4-Dimethyl-4-Silapentane-1-Sulfonate 
DMEM  Dulbecco’s Modified Eagle’s Medium 
env   HIV-1 Envelope Protein 
FACS   Fluorescence Activated Cell Sorting 
FCS   Fetal Calf Serum 
FDA   Food and Drug Administration 
FBC   Fetal Bovine Serum 
GAG   Glycosaminoglycan 
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HPLC  High Performance Chromatography 
HIV   Human Immunodeficiency Virus 
HSQC  Heteronuclear Single-Quantum Coherence 
IC50   Concentration of 50% Inhibition 
IL-8   Interleukin-8 (CXC Chemokine Ligand 8 or CXCL8) 
IPTG   Isopropyl-β-D-Thiogalactopyranoside 
Kd   Dissociation Constant 
MIP   Macrophage Inflammatory Protein (MIP-1α, CCL4; MIP-1β, CCL3) 
MW   Molecular Weight 
NMR   Nuclear Magnetic Resonance 
PBS   Phosphate Buffered Saline 
PBMC  Peripheral Blood mononuclear Cells 
PCR   Polymerase Chain Reaction 
PEEA  Polyethyleneamine 
PEG   Polyethylene Glycol 
PF-4   Platelet Factor 4 (CXCL4) 
PI   Propidium Iodide 
RANTES  Regulated on Activation of Normal T-Cell Expressed and Secreted 
(CCL5) 
RMSD  Root Mean Square Deviation 
RPMI  Roswell Park Memorial Institute 
SD   Standard Deviation 
SDS-PAGE  Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
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TFA   Trifluroacetic Acid 
WT   Wild Type 
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